https://trial.medpath.com/news/allarity-therapeutics-reports-key-progress-in-phase-2-stenoparib-trial-and-strategic 2024-11-19T08:12:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allarity-therapeutics-reports-key-progress-in-phase-2-stenoparib-trial-and-strategic 2024-11-19T08:12:48+00:00 weekly 0.7 https://trial.medpath.com/news/gender-bias-leaves-women-at-risk-in-cardiology-treatment-guidelines-bioworld 2024-11-19T08:09:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gender-bias-leaves-women-at-risk-in-cardiology-treatment-guidelines-bioworld 2024-11-19T08:09:12+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-gets-positive-opinion-on-orphan-drug-designation-for-tobevibar 2024-11-19T08:07:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-gets-positive-opinion-on-orphan-drug-designation-for-tobevibar 2024-11-19T08:07:37+00:00 weekly 0.7 https://trial.medpath.com/news/vir-s-hepatitis-delta-drug-achieves-100-response-rate-in-phase-2-trial-stock-titan 2024-11-19T08:06:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-s-hepatitis-delta-drug-achieves-100-response-rate-in-phase-2-trial-stock-titan 2024-11-19T08:06:52+00:00 weekly 0.7 https://trial.medpath.com/news/theolytics-doses-first-patient-in-phase-i-iia-trial-of-theo-260-in-ovarian-cancer 2024-11-19T08:04:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theolytics-doses-first-patient-in-phase-i-iia-trial-of-theo-260-in-ovarian-cancer 2024-11-19T08:04:08+00:00 weekly 0.7 https://trial.medpath.com/news/nouscom-completes-patient-enrollment-of-randomized-phase-2-globenewswire 2024-11-19T07:15:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nouscom-completes-patient-enrollment-of-randomized-phase-2-globenewswire 2024-11-19T07:15:36+00:00 weekly 0.7 https://trial.medpath.com/news/insilico-medicine-reports-breakthrough-phase-iia-results-for-ai-driven-ipf-drug-ism001-055 2024-11-19T06:56:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insilico-medicine-reports-breakthrough-phase-iia-results-for-ai-driven-ipf-drug-ism001-055 2024-11-19T06:56:43+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-tagrisso-recommended-for-approval-in-eu-by-chmp-for-patients-with 2024-11-19T06:55:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-tagrisso-recommended-for-approval-in-eu-by-chmp-for-patients-with 2024-11-19T06:55:17+00:00 weekly 0.7 https://trial.medpath.com/news/chloroquine-primaquine-therapeutic-response-and-safety-in-patients-with-uncomplicated 2024-11-19T06:34:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chloroquine-primaquine-therapeutic-response-and-safety-in-patients-with-uncomplicated 2024-11-19T06:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/drug-trials-snapshot-miebo-ein-presswire 2024-11-19T06:16:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-trials-snapshot-miebo-ein-presswire 2024-11-19T06:16:32+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-drug-step-closer-to-saving-lives-following-mnd-association-campaign 2024-11-19T06:15:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-drug-step-closer-to-saving-lives-following-mnd-association-campaign 2024-11-19T06:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/zenflow-announces-24-million-financing-round-to-fund-fda-filing-commercial-preparation 2024-11-19T06:12:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zenflow-announces-24-million-financing-round-to-fund-fda-filing-commercial-preparation 2024-11-19T06:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/truebinding-receives-fda-ind-go-ahead-for-parkinson-s-phase-2a-clinical-trial 2024-11-19T06:12:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/truebinding-receives-fda-ind-go-ahead-for-parkinson-s-phase-2a-clinical-trial 2024-11-19T06:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/truebinding-receives-fda-ind-go-ahead-for-parkinson-s-phase-2a-clinical-trial 2024-11-19T06:12:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/truebinding-receives-fda-ind-go-ahead-for-parkinson-s-phase-2a-clinical-trial 2024-11-19T06:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-presents-positive-chronic-hepatitis-delta-clinical-trial-data-and-biospace 2024-11-19T06:12:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-presents-positive-chronic-hepatitis-delta-clinical-trial-data-and-biospace 2024-11-19T06:12:27+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-receives-positive-opinion-on-orphan-drug-designation-for-tobevibart 2024-11-19T06:12:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-receives-positive-opinion-on-orphan-drug-designation-for-tobevibart 2024-11-19T06:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/adicet-opens-enrollment-for-adi-270-phase-1-clinical-trial-in-metastatic-advanced-clear 2024-11-19T06:12:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adicet-opens-enrollment-for-adi-270-phase-1-clinical-trial-in-metastatic-advanced-clear 2024-11-19T06:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/lytix-biopharma-q3-2024-positive-clinical-results-and-strategic-advancements-strengthen 2024-11-19T06:11:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lytix-biopharma-q3-2024-positive-clinical-results-and-strategic-advancements-strengthen 2024-11-19T06:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/oral-muvalaplin-for-lowering-of-lipoprotein-a-a-randomized-clinical-trial-jama-network 2024-11-19T05:48:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oral-muvalaplin-for-lowering-of-lipoprotein-a-a-randomized-clinical-trial-jama-network 2024-11-19T05:48:26+00:00 weekly 0.7 https://trial.medpath.com/news/orano-med-breaks-ground-on-265m-thorium-production-site-radiology-business 2024-11-19T05:40:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/orano-med-breaks-ground-on-265m-thorium-production-site-radiology-business 2024-11-19T05:40:50+00:00 weekly 0.7 https://trial.medpath.com/news/amyloid-related-imaging-abnormalities-in-clinical-trials-of-gantenerumab-in-early 2024-11-19T05:21:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amyloid-related-imaging-abnormalities-in-clinical-trials-of-gantenerumab-in-early 2024-11-19T05:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/resonance-health-expands-clinical-trial-operations-with-sun-pharmaceutical-agreement 2024-11-19T05:10:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/resonance-health-expands-clinical-trial-operations-with-sun-pharmaceutical-agreement 2024-11-19T05:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-reports-positive-phase-3-results-for-tnx-102-sl-in-fibromyalgia 2024-11-19T05:09:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-reports-positive-phase-3-results-for-tnx-102-sl-in-fibromyalgia 2024-11-19T05:09:27+00:00 weekly 0.7 https://trial.medpath.com/news/liquid-biopsies-emerge-as-game-changer-for-rapid-gi-cancer-diagnosis-and-treatment-monitoring 2024-11-19T05:00:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/liquid-biopsies-emerge-as-game-changer-for-rapid-gi-cancer-diagnosis-and-treatment-monitoring 2024-11-19T05:00:10+00:00 weekly 0.7 https://trial.medpath.com/news/ccl2-ccr2-pathway-identified-as-key-driver-of-aggression-in-double-expressor-dlbcl 2024-11-19T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ccl2-ccr2-pathway-identified-as-key-driver-of-aggression-in-double-expressor-dlbcl 2024-11-19T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-blood-test-could-revolutionize-lung-cancer-screening-amid-low-ct-scan-adoption 2024-11-19T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-blood-test-could-revolutionize-lung-cancer-screening-amid-low-ct-scan-adoption 2024-11-19T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-treatment-for-graft-versus-host-disease-labonline 2024-11-19T04:12:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-treatment-for-graft-versus-host-disease-labonline 2024-11-19T04:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/patient-treated-with-neurogene-s-investigational-rett-syndrome-gene-therapy-ngn-401-in 2024-11-19T04:08:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-treated-with-neurogene-s-investigational-rett-syndrome-gene-therapy-ngn-401-in 2024-11-19T04:08:19+00:00 weekly 0.7 https://trial.medpath.com/news/cell-and-gene-therapies-the-global-race-to-cure-everything-pioneering-the-next 2024-11-19T04:04:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cell-and-gene-therapies-the-global-race-to-cure-everything-pioneering-the-next 2024-11-19T04:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/novel-anti-inflammatory-flops-for-hfpef-hfmref-medpage-today 2024-11-19T03:50:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-anti-inflammatory-flops-for-hfpef-hfmref-medpage-today 2024-11-19T03:50:04+00:00 weekly 0.7 https://trial.medpath.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-sana-biotechnology-inc 2024-11-19T03:28:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-sana-biotechnology-inc 2024-11-19T03:28:50+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-presents-positive-chronic-hepatitis-delta-clinical-trial-data-and-morningstar 2024-11-19T02:31:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-presents-positive-chronic-hepatitis-delta-clinical-trial-data-and-morningstar 2024-11-19T02:31:37+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-presents-positive-chronic-hepatitis-delta-clinical-trial-data-yahoo-finance 2024-11-19T02:21:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-presents-positive-chronic-hepatitis-delta-clinical-trial-data-yahoo-finance 2024-11-19T02:21:13+00:00 weekly 0.7 https://trial.medpath.com/news/linerixibat-shows-positive-phase-iii-results-in-cholestatic-pruritus-in-primary-biliary-cholangitis-pbc 2024-11-19T02:11:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/linerixibat-shows-positive-phase-iii-results-in-cholestatic-pruritus-in-primary-biliary-cholangitis-pbc 2024-11-19T02:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/samsung-bioepis-receives-european-approval-for-ophthalmic-disease-treatment-opuviz 2024-11-19T01:55:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/samsung-bioepis-receives-european-approval-for-ophthalmic-disease-treatment-opuviz 2024-11-19T01:55:16+00:00 weekly 0.7 https://trial.medpath.com/news/toripalimab-plus-chemo-approved-in-uk-for-frontline-nasopharyngeal-carcinoma-and-escc 2024-11-19T01:12:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/toripalimab-plus-chemo-approved-in-uk-for-frontline-nasopharyngeal-carcinoma-and-escc 2024-11-19T01:12:52+00:00 weekly 0.7 https://trial.medpath.com/news/secondary-offering-syndax-wins-revuforj-fda-nod-in-km2a-leukemia-bioworld 2024-11-19T00:36:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/secondary-offering-syndax-wins-revuforj-fda-nod-in-km2a-leukemia-bioworld 2024-11-19T00:36:52+00:00 weekly 0.7 https://trial.medpath.com/news/samsung-bioepis-announced-on-the-19th-that-it-has-finally-obtained-product-approval-for-its-eilean-b 2024-11-19T00:34:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/samsung-bioepis-announced-on-the-19th-that-it-has-finally-obtained-product-approval-for-its-eilean-b 2024-11-19T00:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/shanghai-vitalgen-advances-vgr-r01-gene-therapy-to-phase-3-trial-for-bietti-crystalline-dystrophy 2024-11-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shanghai-vitalgen-advances-vgr-r01-gene-therapy-to-phase-3-trial-for-bietti-crystalline-dystrophy 2024-11-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cu-medicine-introduces-asia-s-first-histotripsy-2-0-system-for-liver-tumour-treatment 2024-11-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cu-medicine-introduces-asia-s-first-histotripsy-2-0-system-for-liver-tumour-treatment 2024-11-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-gives-positive-opinion-for-lecanemab-following-re-examination-of-data 2024-11-18T23:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-gives-positive-opinion-for-lecanemab-following-re-examination-of-data 2024-11-18T23:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-rrmm-data-explore-dose-deescalation-and-outpatient-use-of-teclistamab 2024-11-18T22:24:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-rrmm-data-explore-dose-deescalation-and-outpatient-use-of-teclistamab 2024-11-18T22:24:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-authorizes-ai-driven-mri-solution-for-safer-alzheimer-s-treatment 2024-11-18T22:13:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-authorizes-ai-driven-mri-solution-for-safer-alzheimer-s-treatment 2024-11-18T22:13:19+00:00 weekly 0.7 https://trial.medpath.com/news/open-label-extension-data-confirms-sustained-benefit-of-acoramidis-on-cardiovascular-outcomes-including-statistically-significant-reduction-in-acm-within-36-months 2024-11-18T22:11:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/open-label-extension-data-confirms-sustained-benefit-of-acoramidis-on-cardiovascular-outcomes-including-statistically-significant-reduction-in-acm-within-36-months 2024-11-18T22:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/muvalaplin-lowered-lipoprotein-a-levels-in-adults-with-high-risk-for-cardiovascular-events-by-up-to-85-at-highest-tested-dose 2024-11-18T22:11:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/muvalaplin-lowered-lipoprotein-a-levels-in-adults-with-high-risk-for-cardiovascular-events-by-up-to-85-at-highest-tested-dose 2024-11-18T22:11:04+00:00 weekly 0.7 https://trial.medpath.com/news/two-lp-a-lowering-therapies-clear-bar-in-kraken-and-alpacar-tctmd-com 2024-11-18T22:08:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-lp-a-lowering-therapies-clear-bar-in-kraken-and-alpacar-tctmd-com 2024-11-18T22:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-and-only-drug-for-rare-leukemia-managed-healthcare-executive 2024-11-18T22:04:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-and-only-drug-for-rare-leukemia-managed-healthcare-executive 2024-11-18T22:04:44+00:00 weekly 0.7 https://trial.medpath.com/news/ema-grants-orphan-drug-status-to-vir-biotech-hepatitis-treatments-investing-com 2024-11-18T21:56:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-grants-orphan-drug-status-to-vir-biotech-hepatitis-treatments-investing-com 2024-11-18T21:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-new-psoriasis-drug-shows-breakthrough-results-in-phase-3-trial-74-success-rate 2024-11-18T21:33:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-new-psoriasis-drug-shows-breakthrough-results-in-phase-3-trial-74-success-rate 2024-11-18T21:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/incyte-provides-update-on-early-phase-mrgprx2-and-mrgprx4-programs-stock-titan 2024-11-18T21:33:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incyte-provides-update-on-early-phase-mrgprx2-and-mrgprx4-programs-stock-titan 2024-11-18T21:33:22+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-gets-positive-chmp-opinion-for-opdivo-plus-yervoy-to-treat-adult-with 2024-11-18T21:32:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-gets-positive-chmp-opinion-for-opdivo-plus-yervoy-to-treat-adult-with 2024-11-18T21:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-receives-positive-opinion-on-orphan-drug-designation-for-tobevibart 2024-11-18T21:31:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-receives-positive-opinion-on-orphan-drug-designation-for-tobevibart 2024-11-18T21:31:30+00:00 weekly 0.7 https://trial.medpath.com/news/silence-therapeutics-releases-late-breaking-phase-2-zerlasiran-data-daic 2024-11-18T21:29:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/silence-therapeutics-releases-late-breaking-phase-2-zerlasiran-data-daic 2024-11-18T21:29:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-status-to-nipocalimab-for-sjogren-s-disease 2024-11-18T21:23:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-status-to-nipocalimab-for-sjogren-s-disease 2024-11-18T21:23:03+00:00 weekly 0.7 https://trial.medpath.com/news/kraken-oral-muvalaplin-safely-lowers-lp-a-in-early-stage-trial 2024-11-18T21:20:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kraken-oral-muvalaplin-safely-lowers-lp-a-in-early-stage-trial 2024-11-18T21:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/data-continue-to-help-shape-cdk4-6-inhibitor-selection-sequencing-in-hr-breast-cancer 2024-11-18T21:19:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-continue-to-help-shape-cdk4-6-inhibitor-selection-sequencing-in-hr-breast-cancer 2024-11-18T21:19:57+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-receives-positive-opinion-on-orphan-drug-designation-for-tobevibart 2024-11-18T21:17:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-receives-positive-opinion-on-orphan-drug-designation-for-tobevibart 2024-11-18T21:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/grail-launches-fda-approved-phase-3-trial-for-breakthrough-lung-cancer-blood-test 2024-11-18T21:14:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grail-launches-fda-approved-phase-3-trial-for-breakthrough-lung-cancer-blood-test 2024-11-18T21:14:57+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-secures-key-eu-orphan-drug-status-for-hepatitis-delta-treatment 2024-11-18T21:14:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-secures-key-eu-orphan-drug-status-for-hepatitis-delta-treatment 2024-11-18T21:14:47+00:00 weekly 0.7 https://trial.medpath.com/news/toragen-inc-provides-update-on-data-from-ongoing-phase-1-clinical-trial-of-tgn-s11-as 2024-11-18T21:09:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/toragen-inc-provides-update-on-data-from-ongoing-phase-1-clinical-trial-of-tgn-s11-as 2024-11-18T21:09:50+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-announces-fda-acceptance-for-review-of-reproxalap-new-drug 2024-11-18T21:09:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aldeyra-therapeutics-announces-fda-acceptance-for-review-of-reproxalap-new-drug 2024-11-18T21:09:48+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-receives-positive-opinion-on-orphan-drug-designation-for-tobevibart 2024-11-18T21:09:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-receives-positive-opinion-on-orphan-drug-designation-for-tobevibart 2024-11-18T21:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/two-years-after-its-fda-approval-rebyota-continues-to-show-efficacy-and-safety 2024-11-18T21:06:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-years-after-its-fda-approval-rebyota-continues-to-show-efficacy-and-safety 2024-11-18T21:06:28+00:00 weekly 0.7 https://trial.medpath.com/news/cure51-launches-nhs-approved-study-with-cambridge-university-hospitals-and-morningstar 2024-11-18T20:45:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cure51-launches-nhs-approved-study-with-cambridge-university-hospitals-and-morningstar 2024-11-18T20:45:56+00:00 weekly 0.7 https://trial.medpath.com/news/vaccine-for-early-parkinson-s-showing-safety-in-phase-2-trial 2024-11-18T20:29:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaccine-for-early-parkinson-s-showing-safety-in-phase-2-trial 2024-11-18T20:29:23+00:00 weekly 0.7 https://trial.medpath.com/news/alentis-receives-fda-fast-track-designation-for-ale-p02-for-the-treatment-of-cldn1 2024-11-18T20:22:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alentis-receives-fda-fast-track-designation-for-ale-p02-for-the-treatment-of-cldn1 2024-11-18T20:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/antidiabetic-medication-and-asthma-attacks-diabetes-jama-internal-medicine 2024-11-18T20:13:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antidiabetic-medication-and-asthma-attacks-diabetes-jama-internal-medicine 2024-11-18T20:13:48+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-lazertinib-with-amivantamab-to-treat-egfr-mutated-advanced-nsclc 2024-11-18T20:07:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-recommends-lazertinib-with-amivantamab-to-treat-egfr-mutated-advanced-nsclc 2024-11-18T20:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations 2024-11-18T20:04:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations 2024-11-18T20:04:32+00:00 weekly 0.7 https://trial.medpath.com/news/in-a-small-international-trial-novel-oral-medication-muvalaplin-lowered-lp-a 2024-11-18T20:00:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-a-small-international-trial-novel-oral-medication-muvalaplin-lowered-lp-a 2024-11-18T20:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/zetagen-therapeutics-announces-first-patients-enrolled-in-phase-2a-clinical-study-of 2024-11-18T19:52:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zetagen-therapeutics-announces-first-patients-enrolled-in-phase-2a-clinical-study-of 2024-11-18T19:52:38+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-s-revuforj-wins-fda-approval-in-aggressive-form-of-leukemia-endpoints-news 2024-11-18T19:39:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-s-revuforj-wins-fda-approval-in-aggressive-form-of-leukemia-endpoints-news 2024-11-18T19:39:01+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-says-phase-3-trial-of-tirzepatide-met-primary-secondary-endpoints-marketscreener 2024-11-18T19:37:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-says-phase-3-trial-of-tirzepatide-met-primary-secondary-endpoints-marketscreener 2024-11-18T19:37:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-for-revuforj-issued-to-syndax-pharmaceuticals-inc-quantisnow 2024-11-18T19:34:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-for-revuforj-issued-to-syndax-pharmaceuticals-inc-quantisnow 2024-11-18T19:34:32+00:00 weekly 0.7 https://trial.medpath.com/news/novel-drug-can-reduce-lipoprotein-a-by-more-than-80-cleveland-clinic-newsroom 2024-11-18T19:31:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-drug-can-reduce-lipoprotein-a-by-more-than-80-cleveland-clinic-newsroom 2024-11-18T19:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-analysis-of-hemodynamic-effects-of-remimazolam-and-propofo-dddt 2024-11-18T19:31:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparative-analysis-of-hemodynamic-effects-of-remimazolam-and-propofo-dddt 2024-11-18T19:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-promising-for-rare-genetic-cardiomyopathy-medpage-today 2024-11-18T19:25:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-promising-for-rare-genetic-cardiomyopathy-medpage-today 2024-11-18T19:25:33+00:00 weekly 0.7 https://trial.medpath.com/news/scientists-from-barcelona-develop-a-car-t-therapy-for-breast-cancer 2024-11-18T19:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scientists-from-barcelona-develop-a-car-t-therapy-for-breast-cancer 2024-11-18T19:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-pharmaceuticals-presents-new-data-at-aha24-from-palisade-phase-3-study-and-open-label-extension-from-muir-and-shasta-2-studies-of-plozasiran 2024-11-18T19:11:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-presents-new-data-at-aha24-from-palisade-phase-3-study-and-open-label-extension-from-muir-and-shasta-2-studies-of-plozasiran 2024-11-18T19:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-pharmaceuticals-submits-new-drug-application-to-u-s-fda-for-plozasiran-for-the-treatment-of-familial-chylomicronemia-syndrome 2024-11-18T19:11:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-submits-new-drug-application-to-u-s-fda-for-plozasiran-for-the-treatment-of-familial-chylomicronemia-syndrome 2024-11-18T19:11:13+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-announces-fda-acceptance-for-review-of-reproxalap-new-drug-application-for-the-treatment-of-dry-eye-disease 2024-11-18T19:11:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aldeyra-therapeutics-announces-fda-acceptance-for-review-of-reproxalap-new-drug-application-for-the-treatment-of-dry-eye-disease 2024-11-18T19:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/pulmonary-vein-isolation-with-optimized-linear-ablation-for-persistent-af-jama-network 2024-11-18T19:08:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pulmonary-vein-isolation-with-optimized-linear-ablation-for-persistent-af-jama-network 2024-11-18T19:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/gene-editing-therapy-shows-promise-in-hereditary-angioedema-medpage-today 2024-11-18T19:08:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-editing-therapy-shows-promise-in-hereditary-angioedema-medpage-today 2024-11-18T19:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/siren-biotechnology-reveals-srn-101-as-lead-asset-for-high-grade-gliomas-with-both 2024-11-18T19:06:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/siren-biotechnology-reveals-srn-101-as-lead-asset-for-high-grade-gliomas-with-both 2024-11-18T19:06:20+00:00 weekly 0.7 https://trial.medpath.com/news/infigratinib-demonstrates-positive-phase-2-data-in-children-with-achondroplasia 2024-11-18T18:45:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/infigratinib-demonstrates-positive-phase-2-data-in-children-with-achondroplasia 2024-11-18T18:45:16+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-pharmaceuticals-leukemia-drug-wins-a-first-in-class-fda-approval 2024-11-18T18:32:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-pharmaceuticals-leukemia-drug-wins-a-first-in-class-fda-approval 2024-11-18T18:32:49+00:00 weekly 0.7 https://trial.medpath.com/news/first-brain-injected-gene-therapy-approved-by-fda-webmd 2024-11-18T18:27:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-brain-injected-gene-therapy-approved-by-fda-webmd 2024-11-18T18:27:36+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-s-outlook-dims-as-analyst-projects-flat-revenue-until-2026-yahoo-finance 2024-11-18T18:23:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-s-outlook-dims-as-analyst-projects-flat-revenue-until-2026-yahoo-finance 2024-11-18T18:23:51+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-s-outlook-dims-as-analyst-projects-flat-revenue-until-2026-benzinga 2024-11-18T18:23:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-s-outlook-dims-as-analyst-projects-flat-revenue-until-2026-benzinga 2024-11-18T18:23:17+00:00 weekly 0.7 https://trial.medpath.com/news/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations 2024-11-18T18:21:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations 2024-11-18T18:21:30+00:00 weekly 0.7 https://trial.medpath.com/news/celltrion-presents-additional-data-from-phase-iii-randomized-controlled-trials-to-further 2024-11-18T18:21:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celltrion-presents-additional-data-from-phase-iii-randomized-controlled-trials-to-further 2024-11-18T18:21:29+00:00 weekly 0.7 https://trial.medpath.com/news/cellectar-biosciences-reports-financial-results-for-q3-2024-globenewswire 2024-11-18T18:06:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cellectar-biosciences-reports-financial-results-for-q3-2024-globenewswire 2024-11-18T18:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/patient-recruitment-complete-for-high-dose-cohort-of-oral-fasudil-in-phase-2-als-study 2024-11-18T18:06:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-recruitment-complete-for-high-dose-cohort-of-oral-fasudil-in-phase-2-als-study 2024-11-18T18:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/ohsu-tests-crispr-gene-editing-technology-to-treat-deadly-heart-condition 2024-11-18T17:57:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ohsu-tests-crispr-gene-editing-technology-to-treat-deadly-heart-condition 2024-11-18T17:57:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revumenib-for-certain-patients-with-advanced-acute-leukemia-healio 2024-11-18T17:45:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-revumenib-for-certain-patients-with-advanced-acute-leukemia-healio 2024-11-18T17:45:43+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-reports-promising-phase-ii-results-for-recurrent-pericarditis-therapy 2024-11-18T17:37:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-therapeutics-reports-promising-phase-ii-results-for-recurrent-pericarditis-therapy 2024-11-18T17:37:24+00:00 weekly 0.7 https://trial.medpath.com/news/think-surgical-receives-fda-510-k-clearance-for-use-of-linksymphoknee-lsk 2024-11-18T17:36:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/think-surgical-receives-fda-510-k-clearance-for-use-of-linksymphoknee-lsk 2024-11-18T17:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-sheds-light-on-a-surprising-connection-between-covid-19-and-cancer-regression 2024-11-18T17:28:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-research-sheds-light-on-a-surprising-connection-between-covid-19-and-cancer-regression 2024-11-18T17:28:49+00:00 weekly 0.7 https://trial.medpath.com/news/niaid-exercises-option-to-continue-preclinical-development-of-bolder-biotechnology-s-bbt 2024-11-18T17:27:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/niaid-exercises-option-to-continue-preclinical-development-of-bolder-biotechnology-s-bbt 2024-11-18T17:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-companion-diagnostic-for-tepotinib-in-mnsclc-harboring-met-exon-14 2024-11-18T17:26:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-companion-diagnostic-for-tepotinib-in-mnsclc-harboring-met-exon-14 2024-11-18T17:26:37+00:00 weekly 0.7 https://trial.medpath.com/news/bylvay-r-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid 2024-11-18T17:25:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bylvay-r-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid 2024-11-18T17:25:54+00:00 weekly 0.7 https://trial.medpath.com/news/the-european-commission-approves-biosimilar-referencing-aflibercept-by-samsung-bioepis 2024-11-18T17:22:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-european-commission-approves-biosimilar-referencing-aflibercept-by-samsung-bioepis 2024-11-18T17:22:29+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-secures-fda-ok-for-new-kind-of-leukemia-drug-biopharma-dive 2024-11-18T17:19:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-secures-fda-ok-for-new-kind-of-leukemia-drug-biopharma-dive 2024-11-18T17:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/tennor-s-phase-iii-antibiotic-trial-meets-all-primary-endpoints-yahoo 2024-11-18T17:14:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tennor-s-phase-iii-antibiotic-trial-meets-all-primary-endpoints-yahoo 2024-11-18T17:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/elite-pharmaceuticals-receives-fda-approval-for-generic-vyvanse-the-shoreline-beacon 2024-11-18T17:11:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elite-pharmaceuticals-receives-fda-approval-for-generic-vyvanse-the-shoreline-beacon 2024-11-18T17:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-phase-ii-maveric-pilot-clinical-results-in-recurrent-pericarditis 2024-11-18T17:10:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-therapeutics-phase-ii-maveric-pilot-clinical-results-in-recurrent-pericarditis 2024-11-18T17:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-phase-ii-maveric-pilot-clinical-results-in-recurrent-pericarditis-biospace 2024-11-18T17:09:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-therapeutics-phase-ii-maveric-pilot-clinical-results-in-recurrent-pericarditis-biospace 2024-11-18T17:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/trial-of-cf-gene-therapy-sp-101-begins-dosing-is-still-recruiting 2024-11-18T17:02:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-of-cf-gene-therapy-sp-101-begins-dosing-is-still-recruiting 2024-11-18T17:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/tennor-announces-positive-topline-results-from-rifasutenizol-phase-iii-trial-for-h-pylori-infection 2024-11-18T17:02:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tennor-announces-positive-topline-results-from-rifasutenizol-phase-iii-trial-for-h-pylori-infection 2024-11-18T17:02:02+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-positive-chmp-opinion-for-lazcluze-in-lung-cancer-marketscreener 2024-11-18T17:01:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-positive-chmp-opinion-for-lazcluze-in-lung-cancer-marketscreener 2024-11-18T17:01:57+00:00 weekly 0.7 https://trial.medpath.com/news/daily-tablet-shows-promise-in-treating-achondroplasia-in-children-news-medical 2024-11-18T16:59:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daily-tablet-shows-promise-in-treating-achondroplasia-in-children-news-medical 2024-11-18T16:59:21+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-trial-of-rock-inhibitor-bravyl-now-fully-enrolled-als-news-today 2024-11-18T16:58:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-trial-of-rock-inhibitor-bravyl-now-fully-enrolled-als-news-today 2024-11-18T16:58:45+00:00 weekly 0.7 https://trial.medpath.com/news/new-technique-may-allow-for-visualization-of-car-t-cells-postinjection-the-asco-post 2024-11-18T16:57:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-technique-may-allow-for-visualization-of-car-t-cells-postinjection-the-asco-post 2024-11-18T16:57:40+00:00 weekly 0.7 https://trial.medpath.com/news/histosonics-enrolls-first-patients-in-histotripsy-master-study-massdevice 2024-11-18T16:49:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/histosonics-enrolls-first-patients-in-histotripsy-master-study-massdevice 2024-11-18T16:49:55+00:00 weekly 0.7 https://trial.medpath.com/news/brightheart-earns-fda-clearance-for-ai-powered-prenatal-heart-ultrasound-tech 2024-11-18T16:49:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brightheart-earns-fda-clearance-for-ai-powered-prenatal-heart-ultrasound-tech 2024-11-18T16:49:54+00:00 weekly 0.7 https://trial.medpath.com/news/radiotherapy-with-cetuximab-or-durvalumab-for-advanced-hnscc-2-minute-medicine 2024-11-18T16:47:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiotherapy-with-cetuximab-or-durvalumab-for-advanced-hnscc-2-minute-medicine 2024-11-18T16:47:06+00:00 weekly 0.7 https://trial.medpath.com/news/tennor-s-phase-iii-antibiotic-trial-meets-all-primary-endpoints 2024-11-18T16:44:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tennor-s-phase-iii-antibiotic-trial-meets-all-primary-endpoints 2024-11-18T16:44:24+00:00 weekly 0.7 https://trial.medpath.com/news/barinthus-bio-shares-ongoing-phase-iib-chronic-hepatitis-b-trial-results-clinical-trials-arena 2024-11-18T16:44:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/barinthus-bio-shares-ongoing-phase-iib-chronic-hepatitis-b-trial-results-clinical-trials-arena 2024-11-18T16:44:24+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-mirvetuximab-soravtansine-for-fra-platinum-resistant 2024-11-18T16:43:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-approves-mirvetuximab-soravtansine-for-fra-platinum-resistant 2024-11-18T16:43:15+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-phase-ii-maveric-pilot-clinical-results-in-recurrent-pericarditis 2024-11-18T16:42:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-therapeutics-phase-ii-maveric-pilot-clinical-results-in-recurrent-pericarditis 2024-11-18T16:42:40+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-s-cardiolrx-shows-major-pain-relief-success-in-phase-ii-pericarditis-trial 2024-11-18T16:42:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-s-cardiolrx-shows-major-pain-relief-success-in-phase-ii-pericarditis-trial 2024-11-18T16:42:03+00:00 weekly 0.7 https://trial.medpath.com/news/fda-endorses-speedy-approval-path-for-regenxbio-duchenne-gene-therapy 2024-11-18T16:39:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-endorses-speedy-approval-path-for-regenxbio-duchenne-gene-therapy 2024-11-18T16:39:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-endorses-speedy-approval-path-for-regenxbio-duchenne-gene-therapy 2024-11-18T16:37:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-endorses-speedy-approval-path-for-regenxbio-duchenne-gene-therapy 2024-11-18T16:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-spectral-4dct-for-precision-in-radiation-oncology 2024-11-18T16:35:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-spectral-4dct-for-precision-in-radiation-oncology 2024-11-18T16:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-ovarian-cancer-drug-elahere-gets-approval-in-europe-yahoo-finance 2024-11-18T16:32:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-ovarian-cancer-drug-elahere-gets-approval-in-europe-yahoo-finance 2024-11-18T16:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trial-of-navenibart-for-hae-planned-for-launch-in-early-2025-angioedema-news 2024-11-18T16:27:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trial-of-navenibart-for-hae-planned-for-launch-in-early-2025-angioedema-news 2024-11-18T16:27:51+00:00 weekly 0.7 https://trial.medpath.com/news/ai-tool-aims-to-accelerate-clinical-trial-patient-recruitment-multiple-sclerosis-news-today 2024-11-18T16:26:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-tool-aims-to-accelerate-clinical-trial-patient-recruitment-multiple-sclerosis-news-today 2024-11-18T16:26:36+00:00 weekly 0.7 https://trial.medpath.com/news/repurposed-multiple-sclerosis-drug-may-hold-the-cure-for-failing-memory-study-finds 2024-11-18T16:23:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repurposed-multiple-sclerosis-drug-may-hold-the-cure-for-failing-memory-study-finds 2024-11-18T16:23:59+00:00 weekly 0.7 https://trial.medpath.com/news/brightheart-receives-fda-clearance-for-ai-powered-fetal-heart-ultrasound-software 2024-11-18T16:22:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brightheart-receives-fda-clearance-for-ai-powered-fetal-heart-ultrasound-software 2024-11-18T16:22:38+00:00 weekly 0.7 https://trial.medpath.com/news/pulmonary-vein-isolation-with-optimized-linear-ablation-for-persistent-af-jama-network 2024-11-18T16:21:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pulmonary-vein-isolation-with-optimized-linear-ablation-for-persistent-af-jama-network 2024-11-18T16:21:23+00:00 weekly 0.7 https://trial.medpath.com/news/beyond-pulmonary-vein-isolation-bringing-persistent-atrial-fibrillation-in-line-with-alcohol 2024-11-18T16:21:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beyond-pulmonary-vein-isolation-bringing-persistent-atrial-fibrillation-in-line-with-alcohol 2024-11-18T16:21:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ptc-therapeutics-gene-therapy-for-aadc-deficiency 2024-11-18T16:13:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ptc-therapeutics-gene-therapy-for-aadc-deficiency 2024-11-18T16:13:28+00:00 weekly 0.7 https://trial.medpath.com/news/sacituzumab-tirumotecan-shows-promise-in-pretreated-gynecologic-cancer 2024-11-18T16:07:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sacituzumab-tirumotecan-shows-promise-in-pretreated-gynecologic-cancer 2024-11-18T16:07:30+00:00 weekly 0.7 https://trial.medpath.com/news/177lu-psma-i-t-shows-pfs-benefit-in-mcrpc-targeted-oncology 2024-11-18T16:03:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/177lu-psma-i-t-shows-pfs-benefit-in-mcrpc-targeted-oncology 2024-11-18T16:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/siren-biotechnology-reveals-srn-101-as-lead-asset-for-globenewswire 2024-11-18T16:02:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/siren-biotechnology-reveals-srn-101-as-lead-asset-for-globenewswire 2024-11-18T16:02:09+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-s-gene-editing-therapy-shows-early-potential-in-rare-heart-condition 2024-11-18T15:51:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-s-gene-editing-therapy-shows-early-potential-in-rare-heart-condition 2024-11-18T15:51:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-sets-review-date-for-resubmitted-reproxalap-in-dry-eye-disease 2024-11-18T15:50:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-sets-review-date-for-resubmitted-reproxalap-in-dry-eye-disease 2024-11-18T15:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/marking-20-years-of-precision-medicine-in-lung-cancer-treatment 2024-11-18T15:48:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marking-20-years-of-precision-medicine-in-lung-cancer-treatment 2024-11-18T15:48:25+00:00 weekly 0.7 https://trial.medpath.com/news/crucial-steps-towards-a-cure-my-four-take-homes-from-the-clinical-trials-on-alzheimer-s 2024-11-18T15:48:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crucial-steps-towards-a-cure-my-four-take-homes-from-the-clinical-trials-on-alzheimer-s 2024-11-18T15:48:11+00:00 weekly 0.7 https://trial.medpath.com/news/enveric-biosciences-trims-losses-eyes-key-drug-approval-for-difficult-to-treat-mental 2024-11-18T15:40:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enveric-biosciences-trims-losses-eyes-key-drug-approval-for-difficult-to-treat-mental 2024-11-18T15:40:28+00:00 weekly 0.7 https://trial.medpath.com/news/glycogen-storage-disorders-gsd-competitive-landscape-globenewswire 2024-11-18T15:36:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glycogen-storage-disorders-gsd-competitive-landscape-globenewswire 2024-11-18T15:36:03+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-pharmaceuticals-shares-retain-buy-rating-after-revuforj-approval-by-investing-com 2024-11-18T15:11:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-pharmaceuticals-shares-retain-buy-rating-after-revuforj-approval-by-investing-com 2024-11-18T15:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/discover-upcoming-meetings-fda-action-and-key-insights-in-sclc-and-mcspc 2024-11-18T15:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/discover-upcoming-meetings-fda-action-and-key-insights-in-sclc-and-mcspc 2024-11-18T15:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/adicet-bio-announces-first-lupus-nephritis-patient-dosed-in-phase-1-clinical-trial-of-adi 2024-11-18T15:09:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adicet-bio-announces-first-lupus-nephritis-patient-dosed-in-phase-1-clinical-trial-of-adi 2024-11-18T15:09:53+00:00 weekly 0.7 https://trial.medpath.com/news/japanese-study-finds-diabetes-drug-that-protects-kidney-health-zee-news 2024-11-18T15:04:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/japanese-study-finds-diabetes-drug-that-protects-kidney-health-zee-news 2024-11-18T15:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/amivantamab-lazertinib-combo-approaches-eu-approval-in-egfr-advanced-nsclc 2024-11-18T15:02:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amivantamab-lazertinib-combo-approaches-eu-approval-in-egfr-advanced-nsclc 2024-11-18T15:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-pembrolizumab-to-radiation-therapy-and-surgery-in-stage-iii-soft-tissue 2024-11-18T14:53:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-pembrolizumab-to-radiation-therapy-and-surgery-in-stage-iii-soft-tissue 2024-11-18T14:53:28+00:00 weekly 0.7 https://trial.medpath.com/news/moldova-approves-precision-biosciences-hbv-gene-editing-trial-the-medicine-maker 2024-11-18T14:46:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moldova-approves-precision-biosciences-hbv-gene-editing-trial-the-medicine-maker 2024-11-18T14:46:00+00:00 weekly 0.7 https://trial.medpath.com/news/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-globenewswire 2024-11-18T14:31:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-globenewswire 2024-11-18T14:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/roswell-park-clinical-trial-points-toward-promising-new-therapy-for-most-aggressive-type 2024-11-18T14:28:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roswell-park-clinical-trial-points-toward-promising-new-therapy-for-most-aggressive-type 2024-11-18T14:28:28+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-watchman-flx-demonstrates-superiority-to-anticoagulants-in-study 2024-11-18T14:17:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-scientific-watchman-flx-demonstrates-superiority-to-anticoagulants-in-study 2024-11-18T14:17:31+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-options-provide-effective-management-of-geographic-atrophy 2024-11-18T14:13:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-treatment-options-provide-effective-management-of-geographic-atrophy 2024-11-18T14:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/understanding-tumour-growth-variability-in-breast-cancer-xenograft-models-identifies-parp 2024-11-18T14:07:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/understanding-tumour-growth-variability-in-breast-cancer-xenograft-models-identifies-parp 2024-11-18T14:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/intravenous-infusion-of-exenatide-fails-to-reduce-risks-of-complications-in-heart-surgery-patients 2024-11-18T14:06:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intravenous-infusion-of-exenatide-fails-to-reduce-risks-of-complications-in-heart-surgery-patients 2024-11-18T14:06:19+00:00 weekly 0.7 https://trial.medpath.com/news/novel-immunotherapy-fk-pc101-explored-in-prostate-cancer-trial-targeted-oncology 2024-11-18T14:05:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-immunotherapy-fk-pc101-explored-in-prostate-cancer-trial-targeted-oncology 2024-11-18T14:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/why-merck-rolled-the-dice-on-an-unbelievable-early-stage-brain-cancer-drug-pharmavoice 2024-11-18T14:04:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-merck-rolled-the-dice-on-an-unbelievable-early-stage-brain-cancer-drug-pharmavoice 2024-11-18T14:04:43+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-pharmaceuticals-presents-new-data-at-aha24-from-palisade-phase-3-study 2024-11-18T14:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-presents-new-data-at-aha24-from-palisade-phase-3-study 2024-11-18T14:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-s-livdelzi-shows-promise-in-pbc-clinical-trial 2024-11-18T14:04:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-s-livdelzi-shows-promise-in-pbc-clinical-trial 2024-11-18T14:04:07+00:00 weekly 0.7 https://trial.medpath.com/news/nuvectis-pharma-chairman-buys-98400-in-common-stock-investing-com 2024-11-18T14:01:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nuvectis-pharma-chairman-buys-98400-in-common-stock-investing-com 2024-11-18T14:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/enterobiotix-completes-phase-2-study-recruitment-of-ebx-102-02-in-irritable-bowel-syndrome 2024-11-18T14:01:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enterobiotix-completes-phase-2-study-recruitment-of-ebx-102-02-in-irritable-bowel-syndrome 2024-11-18T14:01:17+00:00 weekly 0.7 https://trial.medpath.com/news/silo-pharma-s-ptsd-drug-shows-breakthrough-results-in-preclinical-study-stock-titan 2024-11-18T14:00:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/silo-pharma-s-ptsd-drug-shows-breakthrough-results-in-preclinical-study-stock-titan 2024-11-18T14:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-ramps-up-in-radiopharma-and-eli-lilly-adds-zepbound-details-stat-news 2024-11-18T13:53:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-ramps-up-in-radiopharma-and-eli-lilly-adds-zepbound-details-stat-news 2024-11-18T13:53:54+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-appoints-freda-nassif-as-chief-commercial-officer-quantisnow 2024-11-18T13:47:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cassava-sciences-appoints-freda-nassif-as-chief-commercial-officer-quantisnow 2024-11-18T13:47:25+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-appoints-freda-nassif-as-chief-commercial-officer-stock-titan 2024-11-18T13:37:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cassava-sciences-appoints-freda-nassif-as-chief-commercial-officer-stock-titan 2024-11-18T13:37:59+00:00 weekly 0.7 https://trial.medpath.com/news/a-real-world-disproportionality-analysis-of-fda-adverse-event-reporting-system-faers 2024-11-18T13:32:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-real-world-disproportionality-analysis-of-fda-adverse-event-reporting-system-faers 2024-11-18T13:32:28+00:00 weekly 0.7 https://trial.medpath.com/news/cerevance-doses-first-patient-in-pivotal-phase-3-arise-globenewswire 2024-11-18T13:32:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cerevance-doses-first-patient-in-pivotal-phase-3-arise-globenewswire 2024-11-18T13:32:03+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-launches-wegovy-in-china-with-prices-well-below-u-s-fortune 2024-11-18T13:31:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-launches-wegovy-in-china-with-prices-well-below-u-s-fortune 2024-11-18T13:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/late-breaker-oral-presentation-showing-new-analysis-from-globenewswire 2024-11-18T13:21:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/late-breaker-oral-presentation-showing-new-analysis-from-globenewswire 2024-11-18T13:21:35+00:00 weekly 0.7 https://trial.medpath.com/news/elite-pharmaceuticals-receives-fda-approval-for-generic-the-woodstock-sentinel-review 2024-11-18T13:19:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elite-pharmaceuticals-receives-fda-approval-for-generic-the-woodstock-sentinel-review 2024-11-18T13:19:54+00:00 weekly 0.7 https://trial.medpath.com/news/actinium-pharmaceuticals-reports-78-6m-cash-position-fda-trial-clearances-in-q3 2024-11-18T13:17:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actinium-pharmaceuticals-reports-78-6m-cash-position-fda-trial-clearances-in-q3 2024-11-18T13:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/vera-therapeutics-appoints-jason-s-carter-as-chief-legal-officer-quantisnow 2024-11-18T13:16:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vera-therapeutics-appoints-jason-s-carter-as-chief-legal-officer-quantisnow 2024-11-18T13:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/larimar-therapeutics-presents-additional-data-from-phase-1-studies-and-phase-2-dose 2024-11-18T13:16:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/larimar-therapeutics-presents-additional-data-from-phase-1-studies-and-phase-2-dose 2024-11-18T13:16:09+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-pharmaceuticals-submits-new-drug-application-to-u-s-fda-for-plozasiran-biospace 2024-11-18T13:16:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-submits-new-drug-application-to-u-s-fda-for-plozasiran-biospace 2024-11-18T13:16:09+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-reports-positive-phase-2-data-for-cyb003-demonstrating-breakthrough-12-month 2024-11-18T13:16:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybin-reports-positive-phase-2-data-for-cyb003-demonstrating-breakthrough-12-month 2024-11-18T13:16:09+00:00 weekly 0.7 https://trial.medpath.com/news/vera-therapeutics-appoints-jason-s-carter-as-chief-legal-officer-globenewswire 2024-11-18T13:13:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vera-therapeutics-appoints-jason-s-carter-as-chief-legal-officer-globenewswire 2024-11-18T13:13:35+00:00 weekly 0.7 https://trial.medpath.com/news/mbx-biosciences-completes-phase-1-trial-of-diabetes-drug-by-investing-com 2024-11-18T13:12:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mbx-biosciences-completes-phase-1-trial-of-diabetes-drug-by-investing-com 2024-11-18T13:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/zolbetuximab-approval-paves-way-for-precision-medicine-in-gastric-and-gej-adenocarcinoma 2024-11-18T13:12:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zolbetuximab-approval-paves-way-for-precision-medicine-in-gastric-and-gej-adenocarcinoma 2024-11-18T13:12:00+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-secures-ec-marketing-nod-for-eylea-biosimilar-afqlir 2024-11-18T13:11:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sandoz-secures-ec-marketing-nod-for-eylea-biosimilar-afqlir 2024-11-18T13:11:50+00:00 weekly 0.7 https://trial.medpath.com/news/surviving-and-thriving-news-cu-anschutz 2024-11-18T13:07:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/surviving-and-thriving-news-cu-anschutz 2024-11-18T13:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/weekly-report-adhd-epilepsy-in-primary-care-resuscitation-guidance-and-more 2024-11-18T13:06:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekly-report-adhd-epilepsy-in-primary-care-resuscitation-guidance-and-more 2024-11-18T13:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/vaderis-receives-fda-fast-track-designation-for-vad044-for-the-treatment-of-hereditary 2024-11-18T13:05:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaderis-receives-fda-fast-track-designation-for-vad044-for-the-treatment-of-hereditary 2024-11-18T13:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/convergent-therapeutics-announces-first-shipments-of-actinium-225-from-cardinal-health 2024-11-18T13:02:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/convergent-therapeutics-announces-first-shipments-of-actinium-225-from-cardinal-health 2024-11-18T13:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/allarity-therapeutics-reports-key-progress-in-phase-2-globenewswire 2024-11-18T13:02:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allarity-therapeutics-reports-key-progress-in-phase-2-globenewswire 2024-11-18T13:02:41+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-says-fda-accepts-nda-for-reproxalap-in-dry-eye-disease 2024-11-18T13:02:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aldeyra-therapeutics-says-fda-accepts-nda-for-reproxalap-in-dry-eye-disease 2024-11-18T13:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/collaboration-fosters-treatment-advancements-for-young-lymphoma-populations 2024-11-18T13:01:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/collaboration-fosters-treatment-advancements-for-young-lymphoma-populations 2024-11-18T13:01:54+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-elahere-receives-eu-approval-for-treating-platinum-resistant-ovarian-cancer 2024-11-18T12:58:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-elahere-receives-eu-approval-for-treating-platinum-resistant-ovarian-cancer 2024-11-18T12:58:36+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-seeks-fda-nod-for-rare-disease-drug-by-investing-com 2024-11-18T12:58:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arrowhead-seeks-fda-nod-for-rare-disease-drug-by-investing-com 2024-11-18T12:58:25+00:00 weekly 0.7 https://trial.medpath.com/news/boston-pharma-carves-out-monthly-treatment-niche-in-mash-with-strong-phase-ii-data 2024-11-18T12:55:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-pharma-carves-out-monthly-treatment-niche-in-mash-with-strong-phase-ii-data 2024-11-18T12:55:23+00:00 weekly 0.7 https://trial.medpath.com/news/teva-and-immunai-partner-to-improve-clinical-decision-making-pharmatimes 2024-11-18T12:49:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-and-immunai-partner-to-improve-clinical-decision-making-pharmatimes 2024-11-18T12:49:41+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-tagrisso-gets-chmp-nod-for-eu-approval-by-investing-com 2024-11-18T12:48:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-tagrisso-gets-chmp-nod-for-eu-approval-by-investing-com 2024-11-18T12:48:21+00:00 weekly 0.7 https://trial.medpath.com/news/elite-pharmaceuticals-receives-fda-approval-for-generic-vyvanse-wiarton-echo 2024-11-18T12:48:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elite-pharmaceuticals-receives-fda-approval-for-generic-vyvanse-wiarton-echo 2024-11-18T12:48:12+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-stock-plummets-following-phase-iii-myopia-trial-failure-yahoo 2024-11-18T12:44:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyenovia-stock-plummets-following-phase-iii-myopia-trial-failure-yahoo 2024-11-18T12:44:03+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-s-fcs-drug-shows-80-triglyceride-reduction-in-fda-application-arwr-stock-news 2024-11-18T12:41:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arrowhead-s-fcs-drug-shows-80-triglyceride-reduction-in-fda-application-arwr-stock-news 2024-11-18T12:41:43+00:00 weekly 0.7 https://trial.medpath.com/news/medicus-pharma-ltd-appoints-faisal-mehmud-md-mrcp-as-chief-medical-officer 2024-11-18T12:41:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicus-pharma-ltd-appoints-faisal-mehmud-md-mrcp-as-chief-medical-officer 2024-11-18T12:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/bms-gets-positive-chmp-opinion-for-opdivo-in-mcrc-treatment 2024-11-18T12:41:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bms-gets-positive-chmp-opinion-for-opdivo-in-mcrc-treatment 2024-11-18T12:41:41+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-reports-positive-phase-2-data-for-cyb003-demonstrating-breakthrough-12-month 2024-11-18T12:39:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybin-reports-positive-phase-2-data-for-cyb003-demonstrating-breakthrough-12-month 2024-11-18T12:39:33+00:00 weekly 0.7 https://trial.medpath.com/news/cellectar-biosciences-inc-sec-10-q-report-tradingview 2024-11-18T12:36:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cellectar-biosciences-inc-sec-10-q-report-tradingview 2024-11-18T12:36:00+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-approval-of-lazcluze-rybrevant-in-eu-for-egfr-mutated-advanced-nsclc 2024-11-18T12:35:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-recommends-approval-of-lazcluze-rybrevant-in-eu-for-egfr-mutated-advanced-nsclc 2024-11-18T12:35:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-syndax-drug-revuforj-for-advanced-leukemia-stat-news 2024-11-18T12:33:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-syndax-drug-revuforj-for-advanced-leukemia-stat-news 2024-11-18T12:33:20+00:00 weekly 0.7 https://trial.medpath.com/news/merck-gains-rights-to-lanova-s-pd-1-vegf-bispecific-antibody-in-deal-worth-over-3-2bn 2024-11-18T12:32:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-gains-rights-to-lanova-s-pd-1-vegf-bispecific-antibody-in-deal-worth-over-3-2bn 2024-11-18T12:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/tennor-announces-positive-topline-results-from-rifasutenizol-phase-iii-trial-for-h-pylori-infection 2024-11-18T12:25:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tennor-announces-positive-topline-results-from-rifasutenizol-phase-iii-trial-for-h-pylori-infection 2024-11-18T12:25:53+00:00 weekly 0.7 https://trial.medpath.com/news/neurogene-provides-update-on-ngn-401-gene-therapy-clinical-trial-for-rett-syndrome 2024-11-18T12:25:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurogene-provides-update-on-ngn-401-gene-therapy-clinical-trial-for-rett-syndrome 2024-11-18T12:25:53+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-announces-fda-acceptance-for-review-of-reproxalap-new-drug 2024-11-18T12:14:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aldeyra-therapeutics-announces-fda-acceptance-for-review-of-reproxalap-new-drug 2024-11-18T12:14:44+00:00 weekly 0.7 https://trial.medpath.com/news/bhagirathbhai-r-dholaria-md-on-evaluating-allogeneic-car-t-p-bcma-allo1-in-r-r 2024-11-18T12:14:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bhagirathbhai-r-dholaria-md-on-evaluating-allogeneic-car-t-p-bcma-allo1-in-r-r 2024-11-18T12:14:35+00:00 weekly 0.7 https://trial.medpath.com/news/ai-algorithm-matches-potential-volunteers-to-clinical-trials-release-tech-explorist 2024-11-18T12:14:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-algorithm-matches-potential-volunteers-to-clinical-trials-release-tech-explorist 2024-11-18T12:14:29+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-reveals-trial-outcomes-of-nucresiran-for-attr-amyloidosis-treatment 2024-11-18T12:13:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-reveals-trial-outcomes-of-nucresiran-for-attr-amyloidosis-treatment 2024-11-18T12:13:35+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-rybrevant-in-combination-with-lazcluze-for-the-first-line-treatment 2024-11-18T12:11:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-recommends-rybrevant-in-combination-with-lazcluze-for-the-first-line-treatment 2024-11-18T12:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-presented-data-and-analyses-of-tnx-102-sl-treatment-effects-on 2024-11-18T12:11:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-presented-data-and-analyses-of-tnx-102-sl-treatment-effects-on 2024-11-18T12:11:31+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-marketscreener 2024-11-18T12:08:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-marketscreener 2024-11-18T12:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/larimar-therapeutics-presents-additional-data-from-phase-1-globenewswire 2024-11-18T12:06:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/larimar-therapeutics-presents-additional-data-from-phase-1-globenewswire 2024-11-18T12:06:13+00:00 weekly 0.7 https://trial.medpath.com/news/rationale-behind-the-recent-fda-pd-1-inhibitor-label-restrictions 2024-11-18T12:05:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rationale-behind-the-recent-fda-pd-1-inhibitor-label-restrictions 2024-11-18T12:05:08+00:00 weekly 0.7 https://trial.medpath.com/news/karyopharm-to-present-selinexor-data-at-the-66th-american-society-of-hematology-annual 2024-11-18T12:02:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/karyopharm-to-present-selinexor-data-at-the-66th-american-society-of-hematology-annual 2024-11-18T12:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-s-fibromyalgia-drug-shows-breakthrough-results-in-phase-3-trial-fda-decision-looming 2024-11-18T12:01:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-s-fibromyalgia-drug-shows-breakthrough-results-in-phase-3-trial-fda-decision-looming 2024-11-18T12:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/adicet-bio-launches-phase-1-trial-for-lupus-drug-with-fda-fast-track-status-acet-stock-news 2024-11-18T12:01:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adicet-bio-launches-phase-1-trial-for-lupus-drug-with-fda-fast-track-status-acet-stock-news 2024-11-18T12:01:38+00:00 weekly 0.7 https://trial.medpath.com/news/immatics-announces-third-quarter-2024-financial-results-business-update-and-first-stock-titan 2024-11-18T12:01:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immatics-announces-third-quarter-2024-financial-results-business-update-and-first-stock-titan 2024-11-18T12:01:33+00:00 weekly 0.7 https://trial.medpath.com/news/brightheart-receives-510-k-clearance-from-fda-for-prenatal-ultrasound-software 2024-11-18T11:54:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brightheart-receives-510-k-clearance-from-fda-for-prenatal-ultrasound-software 2024-11-18T11:54:25+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-bags-eu-nod-for-key-drug-from-immunogen-takeover-pharmaphorum 2024-11-18T11:44:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-bags-eu-nod-for-key-drug-from-immunogen-takeover-pharmaphorum 2024-11-18T11:44:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-syndax-s-revuforj-to-treat-leukaemia-yahoo-finance 2024-11-18T11:42:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-syndax-s-revuforj-to-treat-leukaemia-yahoo-finance 2024-11-18T11:42:46+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-stock-plummets-following-phase-iii-myopia-trial-failure 2024-11-18T11:40:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyenovia-stock-plummets-following-phase-iii-myopia-trial-failure 2024-11-18T11:40:16+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-grants-rare-paediatric-disease-designation-to-alveogene-s-novel-inhaled-gene 2024-11-18T11:31:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-grants-rare-paediatric-disease-designation-to-alveogene-s-novel-inhaled-gene 2024-11-18T11:31:20+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-gets-positive-chmp-opinion-for-opdivo-plus-yervoy-to-treat-adult-with 2024-11-18T11:27:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-gets-positive-chmp-opinion-for-opdivo-plus-yervoy-to-treat-adult-with 2024-11-18T11:27:53+00:00 weekly 0.7 https://trial.medpath.com/news/elite-pharmaceuticals-receives-fda-approval-for-generic-vyvanse-stock-titan 2024-11-18T11:15:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elite-pharmaceuticals-receives-fda-approval-for-generic-vyvanse-stock-titan 2024-11-18T11:15:42+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-elahere-wins-european-approval-for-certain-ovarian-cancers 2024-11-18T11:10:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-elahere-wins-european-approval-for-certain-ovarian-cancers 2024-11-18T11:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/teprotumumab-ted-treatment-shows-benefits-for-patients 2024-11-18T11:06:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teprotumumab-ted-treatment-shows-benefits-for-patients 2024-11-18T11:06:28+00:00 weekly 0.7 https://trial.medpath.com/news/elite-pharmaceuticals-receives-fda-approval-for-generic-vyvanse-yahoo-finance 2024-11-18T11:05:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elite-pharmaceuticals-receives-fda-approval-for-generic-vyvanse-yahoo-finance 2024-11-18T11:05:28+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-schizophrenia-treatment-what-the-approval-of-cobenfy-could-mean-for-handling 2024-11-18T11:03:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-new-schizophrenia-treatment-what-the-approval-of-cobenfy-could-mean-for-handling 2024-11-18T11:03:11+00:00 weekly 0.7 https://trial.medpath.com/news/greenwich-lifesciences-provides-update-on-corporate-events-globenewswire 2024-11-18T11:02:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/greenwich-lifesciences-provides-update-on-corporate-events-globenewswire 2024-11-18T11:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/hopemed-hopes-for-first-line-inroads-in-endometriosis-associated-pain-citeline 2024-11-18T10:53:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hopemed-hopes-for-first-line-inroads-in-endometriosis-associated-pain-citeline 2024-11-18T10:53:05+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-plozasiran-demonstrates-promising-phase-iii-results-in-fcs-adults 2024-11-18T10:46:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aha-2024-plozasiran-demonstrates-promising-phase-iii-results-in-fcs-adults 2024-11-18T10:46:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-syndax-s-revuforj-to-treat-leukaemia-pharmaceutical-technology 2024-11-18T10:45:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-syndax-s-revuforj-to-treat-leukaemia-pharmaceutical-technology 2024-11-18T10:45:15+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-pharma-announces-publication-in-the-new-england-journal-of-medicine-of-phase 2024-11-18T10:41:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-pharma-announces-publication-in-the-new-england-journal-of-medicine-of-phase 2024-11-18T10:41:50+00:00 weekly 0.7 https://trial.medpath.com/news/tagrisso-recommended-for-eu-approval-laura-company-announcement-markets-data 2024-11-18T10:38:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tagrisso-recommended-for-eu-approval-laura-company-announcement-markets-data 2024-11-18T10:38:11+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-pharma-announces-publication-in-the-new-england-globenewswire 2024-11-18T10:36:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-pharma-announces-publication-in-the-new-england-globenewswire 2024-11-18T10:36:30+00:00 weekly 0.7 https://trial.medpath.com/news/cure51-launches-nhs-approved-study-with-cambridge-university-hospitals-and-pharmiweb-com 2024-11-18T10:30:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cure51-launches-nhs-approved-study-with-cambridge-university-hospitals-and-pharmiweb-com 2024-11-18T10:30:11+00:00 weekly 0.7 https://trial.medpath.com/news/nih-ai-links-volunteers-to-clinical-trials-mirage-news 2024-11-18T10:25:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-ai-links-volunteers-to-clinical-trials-mirage-news 2024-11-18T10:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-lerodalciep-provides-promising-results-in-open-label-extension-trial-liberate-ole 2024-11-18T10:25:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aha-2024-lerodalciep-provides-promising-results-in-open-label-extension-trial-liberate-ole 2024-11-18T10:25:18+00:00 weekly 0.7 https://trial.medpath.com/news/oral-drug-safe-effective-in-kids-with-achondroplasia-medpage-today 2024-11-18T10:02:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oral-drug-safe-effective-in-kids-with-achondroplasia-medpage-today 2024-11-18T10:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/i-was-hoping-for-12-18-months-here-i-am-14-years-later-sue-s-ovarian-cancer-story 2024-11-18T10:02:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-was-hoping-for-12-18-months-here-i-am-14-years-later-sue-s-ovarian-cancer-story 2024-11-18T10:02:02+00:00 weekly 0.7 https://trial.medpath.com/news/a-stronger-ozempic-is-coming-what-to-know-about-cagrisema-novo-nordisk-s-new-weight-loss-drug 2024-11-18T10:01:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-stronger-ozempic-is-coming-what-to-know-about-cagrisema-novo-nordisk-s-new-weight-loss-drug 2024-11-18T10:01:06+00:00 weekly 0.7 https://trial.medpath.com/news/mdt-perspective-innovative-applications-of-stereotactic-body-radiation-therapy-in-metastatic 2024-11-18T09:27:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mdt-perspective-innovative-applications-of-stereotactic-body-radiation-therapy-in-metastatic 2024-11-18T09:27:50+00:00 weekly 0.7 https://trial.medpath.com/news/enterobiotix-completes-phase-2-study-recruitment-of-ebx-102-02-in-irritable-bowel-syndrome 2024-11-18T09:21:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enterobiotix-completes-phase-2-study-recruitment-of-ebx-102-02-in-irritable-bowel-syndrome 2024-11-18T09:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/nmd-pharma-initiates-phase-2-study-of-nmd670-in-patients-with-charcot-marie-tooth 2024-11-18T09:21:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nmd-pharma-initiates-phase-2-study-of-nmd670-in-patients-with-charcot-marie-tooth 2024-11-18T09:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/trogenix-unveils-revolutionary-platform-to-transform-cancer-treatment-through-precision 2024-11-18T09:21:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trogenix-unveils-revolutionary-platform-to-transform-cancer-treatment-through-precision 2024-11-18T09:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-gets-fda-okay-for-first-in-class-leukaemia-drug-pharmaphorum 2024-11-18T09:14:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-gets-fda-okay-for-first-in-class-leukaemia-drug-pharmaphorum 2024-11-18T09:14:30+00:00 weekly 0.7 https://trial.medpath.com/news/endo-partners-with-paladin-pharma-to-launch-wynzora-cream-in-canada-chemanalyst 2024-11-18T09:13:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endo-partners-with-paladin-pharma-to-launch-wynzora-cream-in-canada-chemanalyst 2024-11-18T09:13:42+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-new-positive-chmp-opinion-for-tagrisso-marketscreener 2024-11-18T08:41:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-new-positive-chmp-opinion-for-tagrisso-marketscreener 2024-11-18T08:41:58+00:00 weekly 0.7 https://trial.medpath.com/news/can-the-integration-of-new-rules-into-a-clinical-decision-support-system-reduce-the-incidence 2024-11-18T08:37:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-the-integration-of-new-rules-into-a-clinical-decision-support-system-reduce-the-incidence 2024-11-18T08:37:25+00:00 weekly 0.7 https://trial.medpath.com/news/brightheart-secures-fda-clearance-for-first-ai-software-revolutionizing-prenatal-fetal 2024-11-18T08:26:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brightheart-secures-fda-clearance-for-first-ai-software-revolutionizing-prenatal-fetal 2024-11-18T08:26:25+00:00 weekly 0.7 https://trial.medpath.com/news/ema-s-chmp-recommends-approval-of-bms-opdivo-pharmaceutical-technology 2024-11-18T08:20:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-s-chmp-recommends-approval-of-bms-opdivo-pharmaceutical-technology 2024-11-18T08:20:30+00:00 weekly 0.7 https://trial.medpath.com/news/cure51-launches-nhs-approved-study-with-cambridge-university-hospitals-and-seven 2024-11-18T08:07:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cure51-launches-nhs-approved-study-with-cambridge-university-hospitals-and-seven 2024-11-18T08:07:23+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-reports-outcomes-from-phase-iii-trial-of-tirzepatide-for-hfpef 2024-11-18T08:00:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-reports-outcomes-from-phase-iii-trial-of-tirzepatide-for-hfpef 2024-11-18T08:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-dupixent-resubmission-for-review-in-chronic-spontaneous-urticaria-treatment 2024-11-18T07:31:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-dupixent-resubmission-for-review-in-chronic-spontaneous-urticaria-treatment 2024-11-18T07:31:40+00:00 weekly 0.7 https://trial.medpath.com/news/ema-committee-recommends-approval-of-merck-s-keytruda-plus-chemotherapy-as-first-line 2024-11-18T07:29:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-committee-recommends-approval-of-merck-s-keytruda-plus-chemotherapy-as-first-line 2024-11-18T07:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/uk-regulator-mhra-grants-nanomerics-clinical-trials-authorisation-notice-for-its-yahoo-finance 2024-11-18T07:17:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-regulator-mhra-grants-nanomerics-clinical-trials-authorisation-notice-for-its-yahoo-finance 2024-11-18T07:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/biocryst-launches-orladeyo-r-berotralstat-in-ireland-quantisnow 2024-11-18T07:16:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocryst-launches-orladeyo-r-berotralstat-in-ireland-quantisnow 2024-11-18T07:16:57+00:00 weekly 0.7 https://trial.medpath.com/news/lift-biosciences-expands-into-ireland-for-manufacturing-clinical-operations 2024-11-18T07:11:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lift-biosciences-expands-into-ireland-for-manufacturing-clinical-operations 2024-11-18T07:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/trogenix-unveils-revolutionary-platform-to-transform-cancer-globenewswire 2024-11-18T07:04:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trogenix-unveils-revolutionary-platform-to-transform-cancer-globenewswire 2024-11-18T07:04:18+00:00 weekly 0.7 https://trial.medpath.com/news/tagrisso-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-unresectable 2024-11-18T07:03:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tagrisso-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-unresectable 2024-11-18T07:03:09+00:00 weekly 0.7 https://trial.medpath.com/news/positive-data-from-phase-2-scope-trial-with-scib1-company-announcement-investegate 2024-11-18T07:02:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-data-from-phase-2-scope-trial-with-scib1-company-announcement-investegate 2024-11-18T07:02:09+00:00 weekly 0.7 https://trial.medpath.com/news/bylvay-r-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-ipsen 2024-11-18T06:56:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bylvay-r-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-ipsen 2024-11-18T06:56:34+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-elahere-wins-eu-approval-35-better-survival-in-ovarian-cancer-treatment 2024-11-18T06:32:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-elahere-wins-eu-approval-35-better-survival-in-ovarian-cancer-treatment 2024-11-18T06:32:31+00:00 weekly 0.7 https://trial.medpath.com/news/bylvay-r-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid 2024-11-18T06:29:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bylvay-r-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid 2024-11-18T06:29:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-johnson-johnson-s-nipocalimab-mychesco 2024-11-18T06:29:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-johnson-johnson-s-nipocalimab-mychesco 2024-11-18T06:29:16+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-abbvie-s-elahere-for-platinum-resistant-ovarian 2024-11-18T06:26:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-approves-abbvie-s-elahere-for-platinum-resistant-ovarian 2024-11-18T06:26:57+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-announces-first-clinical-evidence-from-ongoing-phase-1-study-that-nexiguran-biospace 2024-11-18T06:26:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-announces-first-clinical-evidence-from-ongoing-phase-1-study-that-nexiguran-biospace 2024-11-18T06:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-announces-interim-phase-1-data-of-nucresiran-aln-ttrsc04-showing-rapid 2024-11-18T06:26:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-announces-interim-phase-1-data-of-nucresiran-aln-ttrsc04-showing-rapid 2024-11-18T06:26:29+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-targeted-technology-receives-fast-track-2-4m-grant-to-develop-an-innovative 2024-11-18T06:26:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-targeted-technology-receives-fast-track-2-4m-grant-to-develop-an-innovative 2024-11-18T06:26:29+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-receives-european-commission-approval-of-elahere-r-mirvetuximab-quantisnow 2024-11-18T06:17:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-receives-european-commission-approval-of-elahere-r-mirvetuximab-quantisnow 2024-11-18T06:17:05+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-ce-mark-for-ventana-folr1-folr1-2-1-rxdx-assay-as-the-first-ihc 2024-11-18T06:17:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-receives-ce-mark-for-ventana-folr1-folr1-2-1-rxdx-assay-as-the-first-ihc 2024-11-18T06:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/nmd-pharma-initiates-phase-2-study-of-nmd670-in-patients-globenewswire 2024-11-18T06:16:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nmd-pharma-initiates-phase-2-study-of-nmd670-in-patients-globenewswire 2024-11-18T06:16:33+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-sequana-medical-announces-strong-24-month-globenewswire 2024-11-18T06:16:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-sequana-medical-announces-strong-24-month-globenewswire 2024-11-18T06:16:32+00:00 weekly 0.7 https://trial.medpath.com/news/bylvay-r-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels 2024-11-18T06:14:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bylvay-r-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels 2024-11-18T06:14:33+00:00 weekly 0.7 https://trial.medpath.com/news/bylvay-r-odevixibat-data-shows-sustained-improvement-in-globenewswire 2024-11-18T06:08:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bylvay-r-odevixibat-data-shows-sustained-improvement-in-globenewswire 2024-11-18T06:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/roche-secures-ce-mark-for-breakthrough-ovarian-cancer-diagnostic-test-rhhby-stock-news 2024-11-18T06:06:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-secures-ce-mark-for-breakthrough-ovarian-cancer-diagnostic-test-rhhby-stock-news 2024-11-18T06:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-receives-european-commission-approval-of-elahere-r-mirvetuximab 2024-11-18T06:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-receives-european-commission-approval-of-elahere-r-mirvetuximab 2024-11-18T06:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin-biospace 2024-11-18T06:03:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin-biospace 2024-11-18T06:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-pharma-globenewswire-via-ritzau 2024-11-18T06:03:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipsen-pharma-globenewswire-via-ritzau 2024-11-18T06:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/samsung-bioepis-gets-positive-ema-opinion-for-biosimilars-targeting-amgen-s-prolia-xgeva 2024-11-18T06:02:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/samsung-bioepis-gets-positive-ema-opinion-for-biosimilars-targeting-amgen-s-prolia-xgeva 2024-11-18T06:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/child-thriving-after-becoming-world-s-youngest-to-receive-gene-therapy-for-aadc-deficiency 2024-11-18T05:55:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/child-thriving-after-becoming-world-s-youngest-to-receive-gene-therapy-for-aadc-deficiency 2024-11-18T05:55:38+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-s-livdelzi-seladelpar-demonstrated-a-sustained-efficacy-and-long-term-safety 2024-11-18T05:49:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-s-livdelzi-seladelpar-demonstrated-a-sustained-efficacy-and-long-term-safety 2024-11-18T05:49:38+00:00 weekly 0.7 https://trial.medpath.com/news/formycon-receives-positive-chmp-opinion-for-fyb203-aflibercept-a-biosimilar-candidate 2024-11-18T05:32:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/formycon-receives-positive-chmp-opinion-for-fyb203-aflibercept-a-biosimilar-candidate 2024-11-18T05:32:49+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-accepts-for-review-the-resubmission-of-sbla-for-dupixent-to-treat-chronic 2024-11-18T05:28:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-accepts-for-review-the-resubmission-of-sbla-for-dupixent-to-treat-chronic 2024-11-18T05:28:59+00:00 weekly 0.7 https://trial.medpath.com/news/theralase-r-closes-non-brokered-private-placement-biospace 2024-11-18T05:27:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theralase-r-closes-non-brokered-private-placement-biospace 2024-11-18T05:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/bio-path-holdings-reports-third-quarter-2024-financial-results-biospace 2024-11-18T05:27:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bio-path-holdings-reports-third-quarter-2024-financial-results-biospace 2024-11-18T05:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-setback-gives-bms-commanding-lead-in-schizophrenia-space-biospace 2024-11-18T05:14:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-setback-gives-bms-commanding-lead-in-schizophrenia-space-biospace 2024-11-18T05:14:18+00:00 weekly 0.7 https://trial.medpath.com/news/two-antibody-therapy-drugs-to-fight-covid-19-get-approval-from-eu-health-body 2024-11-18T04:57:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-antibody-therapy-drugs-to-fight-covid-19-get-approval-from-eu-health-body 2024-11-18T04:57:24+00:00 weekly 0.7 https://trial.medpath.com/news/sichuan-kelun-biotech-gains-approval-for-skb571-trials-markets-insider 2024-11-18T04:48:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sichuan-kelun-biotech-gains-approval-for-skb571-trials-markets-insider 2024-11-18T04:48:38+00:00 weekly 0.7 https://trial.medpath.com/news/sichuan-kelun-biotech-s-skb535-gains-crucial-drug-approval-markets-insider 2024-11-18T04:48:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sichuan-kelun-biotech-s-skb535-gains-crucial-drug-approval-markets-insider 2024-11-18T04:48:37+00:00 weekly 0.7 https://trial.medpath.com/news/reconditioned-pacemakers-worked-as-well-as-new-ones-american-heart-association 2024-11-18T04:18:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reconditioned-pacemakers-worked-as-well-as-new-ones-american-heart-association 2024-11-18T04:18:53+00:00 weekly 0.7 https://trial.medpath.com/news/neuralink-blindsight-implant-receives-fda-breakthrough-designation-usa-herald 2024-11-18T04:07:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuralink-blindsight-implant-receives-fda-breakthrough-designation-usa-herald 2024-11-18T04:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-pharmaceuticals-launches-promising-prostate-cancer-trial-markets-insider 2024-11-18T03:49:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clarity-pharmaceuticals-launches-promising-prostate-cancer-trial-markets-insider 2024-11-18T03:49:44+00:00 weekly 0.7 https://trial.medpath.com/news/isla-101-phase-2a-b-protect-clinical-trial-progress-update-inn 2024-11-18T03:43:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/isla-101-phase-2a-b-protect-clinical-trial-progress-update-inn 2024-11-18T03:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/ema-committee-recommends-approval-of-bristol-myers-repotrectinib-to-treat-advanced-pharmabiz 2024-11-18T03:28:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-committee-recommends-approval-of-bristol-myers-repotrectinib-to-treat-advanced-pharmabiz 2024-11-18T03:28:25+00:00 weekly 0.7 https://trial.medpath.com/news/dental-artificial-intelligence-ai-diagnostic-solution-development-company-ddh-ceo-heo 2024-11-18T02:47:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dental-artificial-intelligence-ai-diagnostic-solution-development-company-ddh-ceo-heo 2024-11-18T02:47:32+00:00 weekly 0.7 https://trial.medpath.com/news/safety-of-simultaneous-vs-sequential-mrna-covid-19-and-inactivated-influenza-vaccines 2024-11-18T02:35:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-of-simultaneous-vs-sequential-mrna-covid-19-and-inactivated-influenza-vaccines 2024-11-18T02:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/ema-astrazeneca-vaccine-not-recommended-for-people-with-capillary-bleeding-syndrome 2024-11-18T02:24:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-astrazeneca-vaccine-not-recommended-for-people-with-capillary-bleeding-syndrome 2024-11-18T02:24:46+00:00 weekly 0.7 https://trial.medpath.com/news/prostate-cancer-cases-set-to-rise-5-78-by-2028-highlighting-critical-need-for-early-detection 2024-11-18T02:22:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prostate-cancer-cases-set-to-rise-5-78-by-2028-highlighting-critical-need-for-early-detection 2024-11-18T02:22:07+00:00 weekly 0.7 https://trial.medpath.com/news/european-regulator-endorses-approving-leclaza-combo-therapy-to-treat-nsclc-kbr 2024-11-18T02:12:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-regulator-endorses-approving-leclaza-combo-therapy-to-treat-nsclc-kbr 2024-11-18T02:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/news-in-brief-inhalerx-neurotech-international-cannabiz 2024-11-18T01:36:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/news-in-brief-inhalerx-neurotech-international-cannabiz 2024-11-18T01:36:17+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-medication-nonadherence-and-drug-drug-interaction-testing-on-the-management-of 2024-11-18T01:31:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-of-medication-nonadherence-and-drug-drug-interaction-testing-on-the-management-of 2024-11-18T01:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/the-global-leader-in-rabies-vaccines-the-serum-free-iterative-rabies-vaccine-of-aim-vaccine 2024-11-18T01:04:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-global-leader-in-rabies-vaccines-the-serum-free-iterative-rabies-vaccine-of-aim-vaccine 2024-11-18T01:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/rona-therapeutics-presented-positive-phase-1-results-of-rn0191-a-novel-sirna-therapy 2024-11-18T01:01:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rona-therapeutics-presented-positive-phase-1-results-of-rn0191-a-novel-sirna-therapy 2024-11-18T01:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/sichuan-kelun-biotech-gains-approval-for-skb571-trials-tipranks-com 2024-11-18T00:24:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sichuan-kelun-biotech-gains-approval-for-skb571-trials-tipranks-com 2024-11-18T00:24:02+00:00 weekly 0.7 https://trial.medpath.com/news/sichuan-kelun-biotech-s-skb535-gains-crucial-drug-approval-tipranks-com 2024-11-18T00:24:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sichuan-kelun-biotech-s-skb535-gains-crucial-drug-approval-tipranks-com 2024-11-18T00:24:01+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-pharmaceuticals-launches-promising-prostate-cancer-trial-tipranks-com 2024-11-18T00:19:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clarity-pharmaceuticals-launches-promising-prostate-cancer-trial-tipranks-com 2024-11-18T00:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-israeli-clinical-trial-is-testing-a-tuberculosis-vaccine-to-prevent-alzheimer-s-opinion 2024-11-18T00:14:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-new-israeli-clinical-trial-is-testing-a-tuberculosis-vaccine-to-prevent-alzheimer-s-opinion 2024-11-18T00:14:05+00:00 weekly 0.7 https://trial.medpath.com/news/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations-for-gildeuretinol-as-a-treatment-for-stargardt-disease 2024-11-18T00:11:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations-for-gildeuretinol-as-a-treatment-for-stargardt-disease 2024-11-18T00:11:54+00:00 weekly 0.7 https://trial.medpath.com/news/icotrokinra-delivered-an-industry-leading-combination-of-significant-skin-clearance-with-demonstrated-tolerability-in-a-once-daily-pill-in-phase-3-topline-results 2024-11-18T00:11:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icotrokinra-delivered-an-industry-leading-combination-of-significant-skin-clearance-with-demonstrated-tolerability-in-a-once-daily-pill-in-phase-3-topline-results 2024-11-18T00:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/quell-therapeutics-and-astrazeneca-advance-car-treg-cell-therapy-for-type-1-diabetes-with-10-million-milestone 2024-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quell-therapeutics-and-astrazeneca-advance-car-treg-cell-therapy-for-type-1-diabetes-with-10-million-milestone 2024-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/restem-presents-phase-1-data-of-its-ulsc-program-in-globenewswire 2024-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/restem-presents-phase-1-data-of-its-ulsc-program-in-globenewswire 2024-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-and-weight-loss-drugs-shown-to-reduce-alcohol-related-hospitalizations-study-finds 2024-11-17T23:05:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diabetes-and-weight-loss-drugs-shown-to-reduce-alcohol-related-hospitalizations-study-finds 2024-11-17T23:05:43+00:00 weekly 0.7 https://trial.medpath.com/news/novel-crispr-cas9-based-promising-in-attr-cardiomyopathy-medpage-today 2024-11-17T23:05:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-crispr-cas9-based-promising-in-attr-cardiomyopathy-medpage-today 2024-11-17T23:05:19+00:00 weekly 0.7 https://trial.medpath.com/news/is-ozempic-the-new-miracle-drug-for-patients-with-osteoporosis-related-knee-pain-ausdoc 2024-11-17T23:02:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-ozempic-the-new-miracle-drug-for-patients-with-osteoporosis-related-knee-pain-ausdoc 2024-11-17T23:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/reduced-bleeding-with-abelacimab-could-transform-atrial-fibrillation-treatment 2024-11-17T23:01:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reduced-bleeding-with-abelacimab-could-transform-atrial-fibrillation-treatment 2024-11-17T23:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/two-treatments-that-don-t-work-for-osteoarthritis-medpage-today 2024-11-17T22:34:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-treatments-that-don-t-work-for-osteoarthritis-medpage-today 2024-11-17T22:34:02+00:00 weekly 0.7 https://trial.medpath.com/news/memphasys-nears-completion-of-key-trial-for-felixtm-system-tipranks-com 2024-11-17T22:04:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/memphasys-nears-completion-of-key-trial-for-felixtm-system-tipranks-com 2024-11-17T22:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/email-nudges-spur-patients-with-a-history-of-acute-mi-to-get-flu-shots-tctmd-com 2024-11-17T22:02:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/email-nudges-spur-patients-with-a-history-of-acute-mi-to-get-flu-shots-tctmd-com 2024-11-17T22:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/email-reminders-improved-flu-shot-rates-in-denmark-notably-among-heart-attack-survivors 2024-11-17T21:48:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/email-reminders-improved-flu-shot-rates-in-denmark-notably-among-heart-attack-survivors 2024-11-17T21:48:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-checking-boxes-on-prea-requirement-exposure-for-otc-acetaminophen-ibuprofen-ndas 2024-11-17T21:44:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-checking-boxes-on-prea-requirement-exposure-for-otc-acetaminophen-ibuprofen-ndas 2024-11-17T21:44:49+00:00 weekly 0.7 https://trial.medpath.com/news/emapalumab-may-improve-response-rates-in-mas-treatment-hcplive 2024-11-17T21:34:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emapalumab-may-improve-response-rates-in-mas-treatment-hcplive 2024-11-17T21:34:42+00:00 weekly 0.7 https://trial.medpath.com/news/in-pci-for-mi-spironolactone-does-not-meet-primary-endpoints-but-may-show-benefit-in-hf 2024-11-17T21:22:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-pci-for-mi-spironolactone-does-not-meet-primary-endpoints-but-may-show-benefit-in-hf 2024-11-17T21:22:14+00:00 weekly 0.7 https://trial.medpath.com/news/glorious-neither-exenatide-nor-restrictive-oxygenation-boost-cv-surgery-outcomes 2024-11-17T21:11:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glorious-neither-exenatide-nor-restrictive-oxygenation-boost-cv-surgery-outcomes 2024-11-17T21:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/barry-a-borlaug-md-impact-of-tirzepatide-on-cardiorenal-end-organ-damage-in-hfpef 2024-11-17T21:05:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/barry-a-borlaug-md-impact-of-tirzepatide-on-cardiorenal-end-organ-damage-in-hfpef 2024-11-17T21:05:36+00:00 weekly 0.7 https://trial.medpath.com/news/spironolactone-a-blood-pressure-medication-may-help-reduce-risk-of-new-heart-failure 2024-11-17T21:03:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spironolactone-a-blood-pressure-medication-may-help-reduce-risk-of-new-heart-failure 2024-11-17T21:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/genai-breakthrough-new-drug-shows-promising-results-vs-lung-disease-daily-tribune 2024-11-17T20:55:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genai-breakthrough-new-drug-shows-promising-results-vs-lung-disease-daily-tribune 2024-11-17T20:55:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-moves-to-eliminate-oral-phenylephrine-from-otc-nasal-decongestants 2024-11-17T20:33:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-moves-to-eliminate-oral-phenylephrine-from-otc-nasal-decongestants 2024-11-17T20:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/sarilumab-allows-steroid-taper-more-frequently-vs-methotrexate-in-polymyalgia-rheumatica-healio 2024-11-17T20:23:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarilumab-allows-steroid-taper-more-frequently-vs-methotrexate-in-polymyalgia-rheumatica-healio 2024-11-17T20:23:52+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-inclisiran-shows-efficacy-improved-adherence-for-reducing-ldl-c-pharmacy-times 2024-11-17T19:46:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aha-2024-inclisiran-shows-efficacy-improved-adherence-for-reducing-ldl-c-pharmacy-times 2024-11-17T19:46:00+00:00 weekly 0.7 https://trial.medpath.com/news/medical-researchers-to-test-tarantula-venom-for-potential-epilepsy-treatment-abc-news 2024-11-17T19:45:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medical-researchers-to-test-tarantula-venom-for-potential-epilepsy-treatment-abc-news 2024-11-17T19:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-are-needed-to-develop-new-medicines-for-children-and-teens-living-with-seizures 2024-11-17T18:34:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-are-needed-to-develop-new-medicines-for-children-and-teens-living-with-seizures 2024-11-17T18:34:52+00:00 weekly 0.7 https://trial.medpath.com/news/early-fda-approval-of-revuforj-boosts-syndax-pharmaceuticals-prospects-and-supports 2024-11-17T18:32:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-fda-approval-of-revuforj-boosts-syndax-pharmaceuticals-prospects-and-supports 2024-11-17T18:32:03+00:00 weekly 0.7 https://trial.medpath.com/news/promising-clinical-trial-results-and-future-potential-justify-buy-rating-for-akero-therapeutics 2024-11-17T18:32:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-clinical-trial-results-and-future-potential-justify-buy-rating-for-akero-therapeutics 2024-11-17T18:32:03+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-promising-hepatitis-b-treatment-data-amid-cautious-optimism-and 2024-11-17T18:32:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-promising-hepatitis-b-treatment-data-amid-cautious-optimism-and 2024-11-17T18:32:02+00:00 weekly 0.7 https://trial.medpath.com/news/glorious-exenatide-lacks-preventive-effect-on-organ-injury-in-cardiac-surgery-hcplive 2024-11-17T17:32:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glorious-exenatide-lacks-preventive-effect-on-organ-injury-in-cardiac-surgery-hcplive 2024-11-17T17:32:40+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-presents-new-phase-1-results-for-next-gen-rnai-therapy-nucresiran-in-attr 2024-11-17T15:53:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-presents-new-phase-1-results-for-next-gen-rnai-therapy-nucresiran-in-attr 2024-11-17T15:53:00+00:00 weekly 0.7 https://trial.medpath.com/news/8-health-issues-drugs-like-wegovy-may-treat-besides-weight-loss-study-finds 2024-11-17T15:42:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/8-health-issues-drugs-like-wegovy-may-treat-besides-weight-loss-study-finds 2024-11-17T15:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/intensive-blood-pressure-control-benefits-people-with-type-2-diabetes-too 2024-11-17T15:30:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intensive-blood-pressure-control-benefits-people-with-type-2-diabetes-too 2024-11-17T15:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/white-button-mushroom-extract-shrinks-tumors-and-delays-their-growth-new-atlas 2024-11-17T15:25:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/white-button-mushroom-extract-shrinks-tumors-and-delays-their-growth-new-atlas 2024-11-17T15:25:29+00:00 weekly 0.7 https://trial.medpath.com/news/btk-inhibitor-treatment-options-across-the-lymphoma-landscape-cancer-network 2024-11-17T15:10:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/btk-inhibitor-treatment-options-across-the-lymphoma-landscape-cancer-network 2024-11-17T15:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-s-lisaftoclax-advances-in-drug-approval-markets-insider 2024-11-17T15:01:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascentage-pharma-s-lisaftoclax-advances-in-drug-approval-markets-insider 2024-11-17T15:01:02+00:00 weekly 0.7 https://trial.medpath.com/news/aim-vaccine-s-serum-free-rabies-vaccine-nears-global-market-entry-markets-insider 2024-11-17T15:01:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aim-vaccine-s-serum-free-rabies-vaccine-nears-global-market-entry-markets-insider 2024-11-17T15:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-announces-a-new-drug-application-for-its-novel-bcl-2-inhibitor 2024-11-17T14:54:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascentage-pharma-announces-a-new-drug-application-for-its-novel-bcl-2-inhibitor 2024-11-17T14:54:17+00:00 weekly 0.7 https://trial.medpath.com/news/2d4-a-humanized-monoclonal-antibody-targeting-cd132-is-a-promising-treatment-for-nature 2024-11-17T14:50:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2d4-a-humanized-monoclonal-antibody-targeting-cd132-is-a-promising-treatment-for-nature 2024-11-17T14:50:25+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-announces-interim-phase-1-data-of-nucresiran-aln-ttrsc04-showing-rapid 2024-11-17T14:46:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-announces-interim-phase-1-data-of-nucresiran-aln-ttrsc04-showing-rapid 2024-11-17T14:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-s-nucresiran-achieves-96-ttr-reduction-in-phase-1-attr-amyloidosis-trial 2024-11-17T14:46:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-s-nucresiran-achieves-96-ttr-reduction-in-phase-1-attr-amyloidosis-trial 2024-11-17T14:46:06+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-revolutionizes-heart-failure-treatment-the-pinnacle-gazette 2024-11-17T14:44:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirzepatide-revolutionizes-heart-failure-treatment-the-pinnacle-gazette 2024-11-17T14:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/arbutus-biopharma-s-clinical-trial-shows-promise-for-hepatitis-b-treatment-mychesco 2024-11-17T14:42:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arbutus-biopharma-s-clinical-trial-shows-promise-for-hepatitis-b-treatment-mychesco 2024-11-17T14:42:51+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-announces-interim-phase-1-data-of-nucresiran-aln-ttrsc04-showing-rapid 2024-11-17T14:34:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-announces-interim-phase-1-data-of-nucresiran-aln-ttrsc04-showing-rapid 2024-11-17T14:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/exenatide-a-glp-1-analog-by-iv-during-cardiac-surgery-did-not-reduce-organ-injury-or-death 2024-11-17T14:23:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exenatide-a-glp-1-analog-by-iv-during-cardiac-surgery-did-not-reduce-organ-injury-or-death 2024-11-17T14:23:32+00:00 weekly 0.7 https://trial.medpath.com/news/endometriosis-drug-offers-hope-for-sufferers-who-want-children-daily-mail 2024-11-17T14:10:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endometriosis-drug-offers-hope-for-sufferers-who-want-children-daily-mail 2024-11-17T14:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/is-it-too-late-to-buy-viking-therapeutics-stock 2024-11-17T13:57:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-it-too-late-to-buy-viking-therapeutics-stock 2024-11-17T13:57:04+00:00 weekly 0.7 https://trial.medpath.com/news/ocular-nerve-regrowth-following-use-of-diabetes-drug-modern-retina 2024-11-17T13:47:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocular-nerve-regrowth-following-use-of-diabetes-drug-modern-retina 2024-11-17T13:47:01+00:00 weekly 0.7 https://trial.medpath.com/news/nudge-flu-trial-cardiovascular-focused-messaging-boosts-flu-vaccination-rates-among-heart-attack-survivors 2024-11-17T13:45:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nudge-flu-trial-cardiovascular-focused-messaging-boosts-flu-vaccination-rates-among-heart-attack-survivors 2024-11-17T13:45:44+00:00 weekly 0.7 https://trial.medpath.com/news/the-convergence-of-funding-research-and-collaboration-in-paediatric-brain-cancer-clinical-trials 2024-11-17T13:41:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-convergence-of-funding-research-and-collaboration-in-paediatric-brain-cancer-clinical-trials 2024-11-17T13:41:43+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-announces-a-new-drug-application-for-its-novel-bcl-2-inhibitor-pr-newswire 2024-11-17T13:28:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascentage-pharma-announces-a-new-drug-application-for-its-novel-bcl-2-inhibitor-pr-newswire 2024-11-17T13:28:10+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-ii-trial-of-ipilimumab-nivolumab-or-ipilimumab-and-nivolumab-with-or-without-nature 2024-11-17T13:28:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-ii-trial-of-ipilimumab-nivolumab-or-ipilimumab-and-nivolumab-with-or-without-nature 2024-11-17T13:28:05+00:00 weekly 0.7 https://trial.medpath.com/news/historic-redlining-and-contemporary-racism-linked-to-reduced-life-expectancy-aha-study-reveals 2024-11-17T13:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/historic-redlining-and-contemporary-racism-linked-to-reduced-life-expectancy-aha-study-reveals 2024-11-17T13:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/is-it-too-late-to-buy-viking-therapeutics-stock-the-globe-and-mail 2024-11-17T12:27:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-it-too-late-to-buy-viking-therapeutics-stock-the-globe-and-mail 2024-11-17T12:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/deep-learning-for-oncologic-treatment-outcomes-and-endpoints-evaluation-from-ct-scans-in 2024-11-17T11:06:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deep-learning-for-oncologic-treatment-outcomes-and-endpoints-evaluation-from-ct-scans-in 2024-11-17T11:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-s-lisaftoclax-advances-in-drug-approval-tipranks-com 2024-11-17T10:38:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascentage-pharma-s-lisaftoclax-advances-in-drug-approval-tipranks-com 2024-11-17T10:38:15+00:00 weekly 0.7 https://trial.medpath.com/news/sarclisa-recommended-for-eu-approval-by-chmp-to-treat-transplant-ineligible-newly 2024-11-17T10:31:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarclisa-recommended-for-eu-approval-by-chmp-to-treat-transplant-ineligible-newly 2024-11-17T10:31:15+00:00 weekly 0.7 https://trial.medpath.com/news/eu-regulator-urges-caution-over-russia-s-sputnik-v-vaccine-against-covid-19-telegrafi 2024-11-17T09:57:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-regulator-urges-caution-over-russia-s-sputnik-v-vaccine-against-covid-19-telegrafi 2024-11-17T09:57:52+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-clinical-trial-of-hantaan-and-puumala-virus-dna-vaccines-delivered-by-needle-free-injection 2024-11-17T09:55:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-1-clinical-trial-of-hantaan-and-puumala-virus-dna-vaccines-delivered-by-needle-free-injection 2024-11-17T09:55:13+00:00 weekly 0.7 https://trial.medpath.com/news/mounjaro-appears-to-be-extremely-effective-at-preventing-diabetes-futurism 2024-11-17T09:49:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mounjaro-appears-to-be-extremely-effective-at-preventing-diabetes-futurism 2024-11-17T09:49:35+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-officially-puts-glp-1-meds-on-the-map-for-obesity-related-heart-failure 2024-11-17T09:44:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirzepatide-officially-puts-glp-1-meds-on-the-map-for-obesity-related-heart-failure 2024-11-17T09:44:24+00:00 weekly 0.7 https://trial.medpath.com/news/elafibranor-improves-predicted-transplant-free-survival-based-on-globe-uk-pbc-scores 2024-11-17T09:32:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elafibranor-improves-predicted-transplant-free-survival-based-on-globe-uk-pbc-scores 2024-11-17T09:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/junshi-biosciences-announces-uk-mhra-approval-for-marketing-of-toripalimab 2024-11-17T09:26:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/junshi-biosciences-announces-uk-mhra-approval-for-marketing-of-toripalimab 2024-11-17T09:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-to-acquire-clinical-stage-biotechnology-company-biotheus-medical-dialogues 2024-11-17T08:40:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biontech-to-acquire-clinical-stage-biotechnology-company-biotheus-medical-dialogues 2024-11-17T08:40:18+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-watchman-flxtm-left-atrial-appendage-closure-device-demonstrates 2024-11-17T08:21:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-scientific-watchman-flxtm-left-atrial-appendage-closure-device-demonstrates 2024-11-17T08:21:51+00:00 weekly 0.7 https://trial.medpath.com/news/rivaroxaban-doesn-t-cut-cognitive-decline-stroke-or-tia-in-younger-af-patients 2024-11-17T08:16:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rivaroxaban-doesn-t-cut-cognitive-decline-stroke-or-tia-in-younger-af-patients 2024-11-17T08:16:02+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-therapeutics-reports-promising-phase-1-trial-results-for-nexiguran-ziclumeran-in 2024-11-17T07:31:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-therapeutics-reports-promising-phase-1-trial-results-for-nexiguran-ziclumeran-in 2024-11-17T07:31:57+00:00 weekly 0.7 https://trial.medpath.com/news/acurx-pharmaceuticals-presentation-by-dr-kevin-garey-at-the-peggy-lillis-foundation 2024-11-17T06:05:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acurx-pharmaceuticals-presentation-by-dr-kevin-garey-at-the-peggy-lillis-foundation 2024-11-17T06:05:46+00:00 weekly 0.7 https://trial.medpath.com/news/5-new-weight-loss-drugs-to-watch-in-the-fight-for-the-next-ozempic-aol-com 2024-11-17T05:15:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-new-weight-loss-drugs-to-watch-in-the-fight-for-the-next-ozempic-aol-com 2024-11-17T05:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/academic-and-community-partnerships-forge-new-path-in-comprehensive-cancer-care 2024-11-17T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/academic-and-community-partnerships-forge-new-path-in-comprehensive-cancer-care 2024-11-17T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-jaguar-health-reports-revenue-growth-in-q3-2024-investing-com-nigeria 2024-11-17T04:59:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-jaguar-health-reports-revenue-growth-in-q3-2024-investing-com-nigeria 2024-11-17T04:59:12+00:00 weekly 0.7 https://trial.medpath.com/news/samsung-bioepis-announced-on-the-17th-that-it-received-positive-opinions-on-the-product 2024-11-17T04:16:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/samsung-bioepis-announced-on-the-17th-that-it-received-positive-opinions-on-the-product 2024-11-17T04:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/tce-therapy-demonstrates-quick-responses-for-systemic-lupus-erthematosus-in-early-data 2024-11-17T03:57:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tce-therapy-demonstrates-quick-responses-for-systemic-lupus-erthematosus-in-early-data 2024-11-17T03:57:33+00:00 weekly 0.7 https://trial.medpath.com/news/summit-trial-proves-tirzepatide-s-benefit-in-hfpef-with-obesity-hcplive 2024-11-17T03:52:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summit-trial-proves-tirzepatide-s-benefit-in-hfpef-with-obesity-hcplive 2024-11-17T03:52:36+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-providing-feedback-for-pharmacists-improved-care-for-veterans-with-heart-failure 2024-11-17T03:21:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aha-2024-providing-feedback-for-pharmacists-improved-care-for-veterans-with-heart-failure 2024-11-17T03:21:43+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-says-crispr-therapy-shows-superior-gain-for-cardiomyopathy-patients-stat-news 2024-11-17T03:17:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-says-crispr-therapy-shows-superior-gain-for-cardiomyopathy-patients-stat-news 2024-11-17T03:17:31+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-lowered-risk-of-worsening-heart-failure-and-cvd-death-for-obese-adults 2024-11-17T03:04:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirzepatide-lowered-risk-of-worsening-heart-failure-and-cvd-death-for-obese-adults 2024-11-17T03:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/molecular-testing-reshapes-treatment-landscape-in-advanced-pancreatic-cancer-highlighting-promise-of-ras-inhibitors 2024-11-17T03:00:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/molecular-testing-reshapes-treatment-landscape-in-advanced-pancreatic-cancer-highlighting-promise-of-ras-inhibitors 2024-11-17T03:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/new-car-t-cell-therapy-breakthrough-brings-new-hope-for-treating-deadly-brain 2024-11-17T02:48:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-car-t-cell-therapy-breakthrough-brings-new-hope-for-treating-deadly-brain 2024-11-17T02:48:30+00:00 weekly 0.7 https://trial.medpath.com/news/there-is-a-clear-link-between-rare-cases-of-blood-clots-and-astrazeneca-vaccine-says 2024-11-17T02:34:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/there-is-a-clear-link-between-rare-cases-of-blood-clots-and-astrazeneca-vaccine-says 2024-11-17T02:34:42+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-presents-additional-data-from-galactic-hf-at-the-american-heart-quantisnow 2024-11-17T02:16:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-presents-additional-data-from-galactic-hf-at-the-american-heart-quantisnow 2024-11-17T02:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/subcutaneous-infliximab-ct-p13-superior-to-placebo-as-maintenance-therapy-for-ibd 2024-11-17T00:09:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/subcutaneous-infliximab-ct-p13-superior-to-placebo-as-maintenance-therapy-for-ibd 2024-11-17T00:09:42+00:00 weekly 0.7 https://trial.medpath.com/news/cumberland-pharma-reports-key-clinical-and-business-developments-in-november-2024 2024-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cumberland-pharma-reports-key-clinical-and-business-developments-in-november-2024 2024-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-receives-positive-eu-chmp-opinion-for-pembrolizumab-plus-chemotherapy-as-first 2024-11-16T23:37:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-receives-positive-eu-chmp-opinion-for-pembrolizumab-plus-chemotherapy-as-first 2024-11-16T23:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-tirzepatide-lowers-risk-of-worsening-heart-failure-cvd-death-in-adults-with-obesity 2024-11-16T23:26:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aha-2024-tirzepatide-lowers-risk-of-worsening-heart-failure-cvd-death-in-adults-with-obesity 2024-11-16T23:26:03+00:00 weekly 0.7 https://trial.medpath.com/news/fda-receives-application-for-dato-dxd-treatment-in-egfr-mutated-nsclc-cure-today 2024-11-16T22:59:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-receives-application-for-dato-dxd-treatment-in-egfr-mutated-nsclc-cure-today 2024-11-16T22:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/foundation-for-sarcoidosis-research-fsr-receives-globenewswire 2024-11-16T22:47:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/foundation-for-sarcoidosis-research-fsr-receives-globenewswire 2024-11-16T22:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/foundation-for-sarcoidosis-research-fsr-receives-confirmation-from-the-department-of 2024-11-16T22:47:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/foundation-for-sarcoidosis-research-fsr-receives-confirmation-from-the-department-of 2024-11-16T22:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/jak-inhibitor-succeeds-in-giant-cell-arteritis-trial-medpage-today 2024-11-16T22:18:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jak-inhibitor-succeeds-in-giant-cell-arteritis-trial-medpage-today 2024-11-16T22:18:05+00:00 weekly 0.7 https://trial.medpath.com/news/vq-101-show-promise-in-interim-phase-1-data-for-gba-parkinson-disease-treatment 2024-11-16T22:09:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vq-101-show-promise-in-interim-phase-1-data-for-gba-parkinson-disease-treatment 2024-11-16T22:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/biomarin-presents-real-world-evidence-further-supporting-safety-and-efficacy-of-quantisnow 2024-11-16T22:06:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomarin-presents-real-world-evidence-further-supporting-safety-and-efficacy-of-quantisnow 2024-11-16T22:06:53+00:00 weekly 0.7 https://trial.medpath.com/news/belantamab-mafodotin-triplet-boosts-os-over-daratumumab-regimen-in-myeloma 2024-11-16T22:05:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belantamab-mafodotin-triplet-boosts-os-over-daratumumab-regimen-in-myeloma 2024-11-16T22:05:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rems-program-shows-promising-results-for-mavacamten-in-hypertrophic-pharmacy-times 2024-11-16T21:44:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rems-program-shows-promising-results-for-mavacamten-in-hypertrophic-pharmacy-times 2024-11-16T21:44:28+00:00 weekly 0.7 https://trial.medpath.com/news/fenofibrate-as-an-adjunct-therapy-for-ulcerative-colitis-targeting-in-dddt 2024-11-16T21:35:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fenofibrate-as-an-adjunct-therapy-for-ulcerative-colitis-targeting-in-dddt 2024-11-16T21:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-announces-first-clinical-evidence-from-ongoing-phase-1-study-that-nexiguran 2024-11-16T21:31:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-announces-first-clinical-evidence-from-ongoing-phase-1-study-that-nexiguran 2024-11-16T21:31:57+00:00 weekly 0.7 https://trial.medpath.com/news/poster-shows-secukinumab-improves-hs-symptoms-and-psychiatric-comorbidities 2024-11-16T21:29:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poster-shows-secukinumab-improves-hs-symptoms-and-psychiatric-comorbidities 2024-11-16T21:29:14+00:00 weekly 0.7 https://trial.medpath.com/news/bluejay-therapeutics-reports-best-in-class-monoclonal-antibody-bjt-778-achieved-100 2024-11-16T21:09:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bluejay-therapeutics-reports-best-in-class-monoclonal-antibody-bjt-778-achieved-100 2024-11-16T21:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/killing-cancer-cells-with-alpha-particles-could-be-the-next-frontier-in-treatment-cbc-news 2024-11-16T21:03:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/killing-cancer-cells-with-alpha-particles-could-be-the-next-frontier-in-treatment-cbc-news 2024-11-16T21:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/abelzeta-s-novel-bispecific-car-t-therapy-shows-promise-for-autoimmune-diseases-in-preclinical-studies 2024-11-16T21:01:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abelzeta-s-novel-bispecific-car-t-therapy-shows-promise-for-autoimmune-diseases-in-preclinical-studies 2024-11-16T21:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin 2024-11-16T20:39:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin 2024-11-16T20:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza 2024-11-16T20:30:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza 2024-11-16T20:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/gastrointestinal-disorders-and-aminotransferase-elevations-cited-as-most-noted-adverse 2024-11-16T20:04:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gastrointestinal-disorders-and-aminotransferase-elevations-cited-as-most-noted-adverse 2024-11-16T20:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-wegovy-mounjaro-how-dangerous-are-they-the-herald 2024-11-16T20:01:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-wegovy-mounjaro-how-dangerous-are-they-the-herald 2024-11-16T20:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-the-preformulated-irrigation-solution-bactisure-r-in-acute-periprosthetic-joint-trials 2024-11-16T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-of-the-preformulated-irrigation-solution-bactisure-r-in-acute-periprosthetic-joint-trials 2024-11-16T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/news/movano-focuses-on-eviemed-ring-fda-review-and-new-b2b-partnerships 2024-11-16T18:58:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/movano-focuses-on-eviemed-ring-fda-review-and-new-b2b-partnerships 2024-11-16T18:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/td-cowen-cuts-ascendis-pharma-target-to-153-keeps-buy-rating-investing-com-uk 2024-11-16T18:52:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/td-cowen-cuts-ascendis-pharma-target-to-153-keeps-buy-rating-investing-com-uk 2024-11-16T18:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/accuracy-of-healthcare-systems-data-for-identifying-cardiovascular-outcomes-after-stroke-due 2024-11-16T18:31:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accuracy-of-healthcare-systems-data-for-identifying-cardiovascular-outcomes-after-stroke-due 2024-11-16T18:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/skye-bioscience-surpasses-50-patient-enrollment-in-cbeyond-phase-2-trial-of-pharmabiz 2024-11-16T18:28:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/skye-bioscience-surpasses-50-patient-enrollment-in-cbeyond-phase-2-trial-of-pharmabiz 2024-11-16T18:28:16+00:00 weekly 0.7 https://trial.medpath.com/news/new-alzheimer-s-drug-only-a-few-eligible-for-treatment-nl-times 2024-11-16T18:10:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-alzheimer-s-drug-only-a-few-eligible-for-treatment-nl-times 2024-11-16T18:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-gene-editing-therapy-shows-promise-as-cardiac-amyloidosis-treatment-in-early-study 2024-11-16T18:02:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crispr-gene-editing-therapy-shows-promise-as-cardiac-amyloidosis-treatment-in-early-study 2024-11-16T18:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/belantamab-mafodotin-triplet-improves-os-in-relapsed-refractory-myeloma 2024-11-16T18:02:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belantamab-mafodotin-triplet-improves-os-in-relapsed-refractory-myeloma 2024-11-16T18:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/expert-discusses-current-trials-in-bladder-cancer-to-watch-for-urology-times 2024-11-16T17:51:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-discusses-current-trials-in-bladder-cancer-to-watch-for-urology-times 2024-11-16T17:51:08+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-s-crispr-therapy-shows-90-disease-protein-reduction-in-key-clinical-trial 2024-11-16T17:50:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-s-crispr-therapy-shows-90-disease-protein-reduction-in-key-clinical-trial 2024-11-16T17:50:09+00:00 weekly 0.7 https://trial.medpath.com/news/usfda-approves-first-gene-therapy-for-treatment-of-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-16T17:27:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/usfda-approves-first-gene-therapy-for-treatment-of-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-16T17:27:47+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-research-accelerates-with-innovative-treatments-the-pinnacle-gazette 2024-11-16T16:51:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-research-accelerates-with-innovative-treatments-the-pinnacle-gazette 2024-11-16T16:51:01+00:00 weekly 0.7 https://trial.medpath.com/news/biomarin-s-voxzogo-shows-remarkable-height-gains-in-452-child-achondroplasia-study 2024-11-16T16:10:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomarin-s-voxzogo-shows-remarkable-height-gains-in-452-child-achondroplasia-study 2024-11-16T16:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-unexplained-changes-in-cholesterol-could-help-identify-adults-at-risk-of-dementia 2024-11-16T16:02:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aha-2024-unexplained-changes-in-cholesterol-could-help-identify-adults-at-risk-of-dementia 2024-11-16T16:02:22+00:00 weekly 0.7 https://trial.medpath.com/news/idorsia-launches-aprocitentan-tryvio-in-us-for-treatment-of-hypertension-hcplive 2024-11-16T15:55:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/idorsia-launches-aprocitentan-tryvio-in-us-for-treatment-of-hypertension-hcplive 2024-11-16T15:55:12+00:00 weekly 0.7 https://trial.medpath.com/news/life-changing-alzheimer-s-drug-is-approved-for-use-to-reduce-cognitive-decline 2024-11-16T15:51:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/life-changing-alzheimer-s-drug-is-approved-for-use-to-reduce-cognitive-decline 2024-11-16T15:51:21+00:00 weekly 0.7 https://trial.medpath.com/news/medicus-pharma-makes-debut-on-nasdaq-raising-4m-to-advance-skin-cancer-trial-icymi 2024-11-16T15:35:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicus-pharma-makes-debut-on-nasdaq-raising-4m-to-advance-skin-cancer-trial-icymi 2024-11-16T15:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-announces-first-clinical-evidence-from-ongoing-globenewswire 2024-11-16T15:31:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-announces-first-clinical-evidence-from-ongoing-globenewswire 2024-11-16T15:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/ema-human-medicine-committee-recommends-approval-of-sanofi-s-sarclisa-to-treat-pharmabiz 2024-11-16T15:29:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-human-medicine-committee-recommends-approval-of-sanofi-s-sarclisa-to-treat-pharmabiz 2024-11-16T15:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/navigating-a-sea-change-in-frontline-urothelial-carcinoma-treatment-onclive 2024-11-16T15:22:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/navigating-a-sea-change-in-frontline-urothelial-carcinoma-treatment-onclive 2024-11-16T15:22:28+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-tirzepatide-shows-38-drop-in-heart-failure-risk-major-weight-loss-in-trial 2024-11-16T15:18:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-s-tirzepatide-shows-38-drop-in-heart-failure-risk-major-weight-loss-in-trial 2024-11-16T15:18:15+00:00 weekly 0.7 https://trial.medpath.com/news/improving-disease-modification-and-immune-responses-in-myelofibrosis-with-pelabresib 2024-11-16T15:05:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improving-disease-modification-and-immune-responses-in-myelofibrosis-with-pelabresib 2024-11-16T15:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-16T15:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-16T15:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/summit-tirzepatide-huge-win-for-hfpef-patients-with-obesity-tctmd-com 2024-11-16T15:03:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summit-tirzepatide-huge-win-for-hfpef-patients-with-obesity-tctmd-com 2024-11-16T15:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/hope-on-the-horizon-nephrologists-emphasize-need-for-innovative-c3g-treatments-as 2024-11-16T15:02:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-on-the-horizon-nephrologists-emphasize-need-for-innovative-c3g-treatments-as 2024-11-16T15:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-to-launch-new-life-saving-cancer-trials-for-three-major-projects-gloucestershire-live 2024-11-16T14:55:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-to-launch-new-life-saving-cancer-trials-for-three-major-projects-gloucestershire-live 2024-11-16T14:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-presents-additional-data-from-galactic-hf-at-the-american-heart-morningstar 2024-11-16T14:43:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-presents-additional-data-from-galactic-hf-at-the-american-heart-morningstar 2024-11-16T14:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/cabaletta-bio-reports-q3-2024-financial-results-and-clinical-trial-advancements 2024-11-16T14:28:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cabaletta-bio-reports-q3-2024-financial-results-and-clinical-trial-advancements 2024-11-16T14:28:33+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-announces-first-subject-dosed-in-the-phase-iii-registrational-trial-of-tyk2 2024-11-16T14:16:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innocare-announces-first-subject-dosed-in-the-phase-iii-registrational-trial-of-tyk2 2024-11-16T14:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/adicet-bio-s-adi-001-shows-breakthrough-car-t-cell-results-in-autoimmune-treatment-study 2024-11-16T14:15:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adicet-bio-s-adi-001-shows-breakthrough-car-t-cell-results-in-autoimmune-treatment-study 2024-11-16T14:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-heart-failure-drug-shows-strong-efficacy-across-age-groups-in-phase-3-trial 2024-11-16T14:15:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-heart-failure-drug-shows-strong-efficacy-across-age-groups-in-phase-3-trial 2024-11-16T14:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/corin-receives-fda-510-k-clearance-of-icona-femoral-stem-healio 2024-11-16T14:07:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corin-receives-fda-510-k-clearance-of-icona-femoral-stem-healio 2024-11-16T14:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-s-one-dose-covid-19-vaccine-gets-green-light-from-eu-regulator 2024-11-16T13:59:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-s-one-dose-covid-19-vaccine-gets-green-light-from-eu-regulator 2024-11-16T13:59:44+00:00 weekly 0.7 https://trial.medpath.com/news/greater-institutional-awareness-crucial-for-driving-biotechnology-adoption-csir 2024-11-16T13:59:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/greater-institutional-awareness-crucial-for-driving-biotechnology-adoption-csir 2024-11-16T13:59:30+00:00 weekly 0.7 https://trial.medpath.com/news/junshi-biosciences-announces-uk-mhra-approval-for-marketing-of-toripalimab 2024-11-16T13:54:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/junshi-biosciences-announces-uk-mhra-approval-for-marketing-of-toripalimab 2024-11-16T13:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T13:41:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T13:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/the-oncfive-top-oncology-articles-for-the-week-of-11-10-onclive 2024-11-16T13:02:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-oncfive-top-oncology-articles-for-the-week-of-11-10-onclive 2024-11-16T13:02:22+00:00 weekly 0.7 https://trial.medpath.com/news/plasma-progranulin-levels-are-correlated-with-left-ventricular-function-recovery-following 2024-11-16T12:28:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plasma-progranulin-levels-are-correlated-with-left-ventricular-function-recovery-following 2024-11-16T12:28:54+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-first-line-pembrolizumab-plus-chemo-for-unresectable-non-onclive 2024-11-16T12:21:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-recommends-first-line-pembrolizumab-plus-chemo-for-unresectable-non-onclive 2024-11-16T12:21:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-aria-detecting-software-nerivio-gains-expanded-indication-fda-approves 2024-11-16T12:04:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-aria-detecting-software-nerivio-gains-expanded-indication-fda-approves 2024-11-16T12:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/tetraspecific-b-nk-cell-better-than-t-cell-engagers-european-biotechnology-magazine 2024-11-16T12:01:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tetraspecific-b-nk-cell-better-than-t-cell-engagers-european-biotechnology-magazine 2024-11-16T12:01:28+00:00 weekly 0.7 https://trial.medpath.com/news/healthcare-providers-critical-for-diversifying-hbv-clinical-trial-recruitment-study-finds 2024-11-16T12:00:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healthcare-providers-critical-for-diversifying-hbv-clinical-trial-recruitment-study-finds 2024-11-16T12:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/christ-hospital-surgeons-perform-fourth-ever-implant-of-total-artificial-heart-wlwt 2024-11-16T11:29:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/christ-hospital-surgeons-perform-fourth-ever-implant-of-total-artificial-heart-wlwt 2024-11-16T11:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/azurity-pharma-gets-us-fda-approval-for-danziten-tablets-the-first-and-only-nilotinib-with-no 2024-11-16T11:28:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/azurity-pharma-gets-us-fda-approval-for-danziten-tablets-the-first-and-only-nilotinib-with-no 2024-11-16T11:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/promising-non-surgical-treatment-for-early-cataracts-insights-from-a-phase-ii-clinical-trial 2024-11-16T11:11:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-non-surgical-treatment-for-early-cataracts-insights-from-a-phase-ii-clinical-trial 2024-11-16T11:11:24+00:00 weekly 0.7 https://trial.medpath.com/news/ema-approves-the-third-dose-of-the-anti-covid-vaccine-telegrafi 2024-11-16T11:09:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-approves-the-third-dose-of-the-anti-covid-vaccine-telegrafi 2024-11-16T11:09:21+00:00 weekly 0.7 https://trial.medpath.com/news/chicago-northwestern-medicine-study-shows-severe-covid-19-may-shrink-cancer-cells 2024-11-16T11:00:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chicago-northwestern-medicine-study-shows-severe-covid-19-may-shrink-cancer-cells 2024-11-16T11:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/icometrix-s-ai-driven-mri-solution-icobrain-aria-receives-us-fda-clearance-for-safer 2024-11-16T10:30:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icometrix-s-ai-driven-mri-solution-icobrain-aria-receives-us-fda-clearance-for-safer 2024-11-16T10:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/usmani-projects-a-future-of-car-t-in-community-for-myeloma-and-other-cancers 2024-11-16T10:10:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/usmani-projects-a-future-of-car-t-in-community-for-myeloma-and-other-cancers 2024-11-16T10:10:27+00:00 weekly 0.7 https://trial.medpath.com/news/europe-approves-leqembi-for-alzheimer-s-treatment-the-pinnacle-gazette 2024-11-16T09:30:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/europe-approves-leqembi-for-alzheimer-s-treatment-the-pinnacle-gazette 2024-11-16T09:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/ema-announces-that-johnson-johnson-causes-rare-blood-clots-telegrafi 2024-11-16T09:22:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-announces-that-johnson-johnson-causes-rare-blood-clots-telegrafi 2024-11-16T09:22:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revumenib-in-kmt2a-rearranged-acute-leukemia-targeted-oncology 2024-11-16T09:22:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-revumenib-in-kmt2a-rearranged-acute-leukemia-targeted-oncology 2024-11-16T09:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/inventiva-will-present-data-from-the-final-analysis-of-the-globenewswire 2024-11-16T09:02:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inventiva-will-present-data-from-the-final-analysis-of-the-globenewswire 2024-11-16T09:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-reports-positive-phase-ii-trial-results-investing-com-uk 2024-11-16T09:00:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-reports-positive-phase-ii-trial-results-investing-com-uk 2024-11-16T09:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-november-15-2024 2024-11-16T08:21:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-r-s-weekly-rewind-november-15-2024 2024-11-16T08:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/ema-committee-recommends-approval-of-eisai-biogen-s-lecanemab-to-treat-early 2024-11-16T07:28:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-committee-recommends-approval-of-eisai-biogen-s-lecanemab-to-treat-early 2024-11-16T07:28:15+00:00 weekly 0.7 https://trial.medpath.com/news/merkel-germany-will-buy-russian-vaccines-if-it-receives-ema-approval-telegrafi 2024-11-16T07:27:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merkel-germany-will-buy-russian-vaccines-if-it-receives-ema-approval-telegrafi 2024-11-16T07:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/mek-inhibitor-scores-big-win-in-adults-children-with-neurofibromatosis-type-1 2024-11-16T07:19:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mek-inhibitor-scores-big-win-in-adults-children-with-neurofibromatosis-type-1 2024-11-16T07:19:42+00:00 weekly 0.7 https://trial.medpath.com/news/lack-of-data-on-the-vaccine-ema-postpones-the-approval-of-sputnik-v-telegrafi 2024-11-16T07:17:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lack-of-data-on-the-vaccine-ema-postpones-the-approval-of-sputnik-v-telegrafi 2024-11-16T07:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/essential-malaria-drug-artemisinin-shows-signs-of-partial-resistance-in-children-contagion-live 2024-11-16T07:11:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/essential-malaria-drug-artemisinin-shows-signs-of-partial-resistance-in-children-contagion-live 2024-11-16T07:11:16+00:00 weekly 0.7 https://trial.medpath.com/news/revumenib-elicits-favorable-efficacy-in-mnpm1-acute-myeloid-leukemia-cancer-network 2024-11-16T07:01:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revumenib-elicits-favorable-efficacy-in-mnpm1-acute-myeloid-leukemia-cancer-network 2024-11-16T07:01:52+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-grants-marketing-authorization-to-aflibercept-biosimilar-from-sandoz-group 2024-11-16T06:15:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-grants-marketing-authorization-to-aflibercept-biosimilar-from-sandoz-group 2024-11-16T06:15:36+00:00 weekly 0.7 https://trial.medpath.com/news/a-multicenter-phase-ii-trial-of-triplet-antiemetic-therapy-with-palonosetron-aprepitant-and-nature 2024-11-16T06:12:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-multicenter-phase-ii-trial-of-triplet-antiemetic-therapy-with-palonosetron-aprepitant-and-nature 2024-11-16T06:12:51+00:00 weekly 0.7 https://trial.medpath.com/news/noam-solomon-bringing-the-human-story-to-ai-pharmaceutical-executive 2024-11-16T05:41:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/noam-solomon-bringing-the-human-story-to-ai-pharmaceutical-executive 2024-11-16T05:41:16+00:00 weekly 0.7 https://trial.medpath.com/news/vtp-300-nivolumab-combination-shows-promise-for-functional-hbv-cure-in-phase-2b-trial 2024-11-16T05:34:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vtp-300-nivolumab-combination-shows-promise-for-functional-hbv-cure-in-phase-2b-trial 2024-11-16T05:34:43+00:00 weekly 0.7 https://trial.medpath.com/news/airway-on-a-chip-could-speed-up-future-drug-and-therapy-development-prweb 2024-11-16T05:16:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/airway-on-a-chip-could-speed-up-future-drug-and-therapy-development-prweb 2024-11-16T05:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/ema-s-chmp-finds-path-to-leqembi-nod-backs-three-other-new-drugs-biocentury 2024-11-16T04:52:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-s-chmp-finds-path-to-leqembi-nod-backs-three-other-new-drugs-biocentury 2024-11-16T04:52:59+00:00 weekly 0.7 https://trial.medpath.com/news/spirovant-sciences-doses-first-subject-in-cystic-fibrosis-gene-therapy-trial 2024-11-16T04:51:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spirovant-sciences-doses-first-subject-in-cystic-fibrosis-gene-therapy-trial 2024-11-16T04:51:39+00:00 weekly 0.7 https://trial.medpath.com/news/os-therapies-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/os-therapies-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/boston-pharmaceuticals-to-announce-positive-phase-2-data-on-efimosfermin-alfa-bos-580 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-pharmaceuticals-to-announce-positive-phase-2-data-on-efimosfermin-alfa-bos-580 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/arbutus-and-barinthus-bio-announce-new-data-from-the-im-prove-ii-trial-showing-that-the 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arbutus-and-barinthus-bio-announce-new-data-from-the-im-prove-ii-trial-showing-that-the 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-and-biospace 2024-11-16T04:20:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-and-biospace 2024-11-16T04:20:06+00:00 weekly 0.7 https://trial.medpath.com/news/cofactor-genomics-expands-clinical-use-of-oncoprism-as-their-ai-enabled-rna-test 2024-11-16T04:20:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cofactor-genomics-expands-clinical-use-of-oncoprism-as-their-ai-enabled-rna-test 2024-11-16T04:20:06+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-provides-update-on-phase-3-chaperone-study-biospace 2024-11-16T04:20:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyenovia-provides-update-on-phase-3-chaperone-study-biospace 2024-11-16T04:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-s-lag-3-adds-to-keytruda-in-first-line-lung-cancer-citeline-news-insights 2024-11-16T04:19:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-s-lag-3-adds-to-keytruda-in-first-line-lung-cancer-citeline-news-insights 2024-11-16T04:19:43+00:00 weekly 0.7 https://trial.medpath.com/news/managing-dual-checkpoint-inhibition-side-effects-in-nsclc-expert-insights-on-treatment-strategies 2024-11-16T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/managing-dual-checkpoint-inhibition-side-effects-in-nsclc-expert-insights-on-treatment-strategies 2024-11-16T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-reports-positive-phase-ii-trial-results-by-investing-com 2024-11-16T03:13:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-reports-positive-phase-ii-trial-results-by-investing-com 2024-11-16T03:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/adverum-biotechnologies-announces-webcast-to-report-52-week-luna-phase-2-clinical 2024-11-16T02:55:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adverum-biotechnologies-announces-webcast-to-report-52-week-luna-phase-2-clinical 2024-11-16T02:55:53+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-globenewswire 2024-11-16T02:31:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-globenewswire 2024-11-16T02:31:28+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T02:30:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T02:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T02:21:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T02:21:14+00:00 weekly 0.7 https://trial.medpath.com/news/life-changing-alzheimer-s-drug-approved-for-use-in-eu-to-reduce-cognitive-decline 2024-11-16T02:11:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/life-changing-alzheimer-s-drug-approved-for-use-in-eu-to-reduce-cognitive-decline 2024-11-16T02:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/eu-approves-life-changing-important-alzheimer-s-drug-which-can-drastically-slow-onset-surrey-live 2024-11-16T02:11:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-approves-life-changing-important-alzheimer-s-drug-which-can-drastically-slow-onset-surrey-live 2024-11-16T02:11:23+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-reports-promising-phase-ii-sarcoma-trial-results-markets-insider 2024-11-16T02:04:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-reports-promising-phase-ii-sarcoma-trial-results-markets-insider 2024-11-16T02:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/fully-loaded-secondary-prevention-studies-of-lecanemab-donanemab-alzforum 2024-11-16T01:21:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fully-loaded-secondary-prevention-studies-of-lecanemab-donanemab-alzforum 2024-11-16T01:21:02+00:00 weekly 0.7 https://trial.medpath.com/news/ema-committee-recommends-repotrectinib-for-lung-cancer-by-investing-com 2024-11-16T01:07:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-committee-recommends-repotrectinib-for-lung-cancer-by-investing-com 2024-11-16T01:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/invivyd-reports-clinical-efficacy-data-from-canopy-phase-3-trial-of-pemivibart 2024-11-16T00:29:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invivyd-reports-clinical-efficacy-data-from-canopy-phase-3-trial-of-pemivibart 2024-11-16T00:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-reports-positive-end-of-treatment-data-from-march-study 2024-11-16T00:14:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-reports-positive-end-of-treatment-data-from-march-study 2024-11-16T00:14:51+00:00 weekly 0.7 https://trial.medpath.com/news/protara-therapeutics-inc-to-present-new-interim-data-from-phase-2-advanced-2-trial-of 2024-11-16T00:10:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protara-therapeutics-inc-to-present-new-interim-data-from-phase-2-advanced-2-trial-of 2024-11-16T00:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/sol-gel-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-16T00:02:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sol-gel-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-16T00:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/nih-funding-opportunities-november-2024-university-of-utah-health 2024-11-16T00:01:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-funding-opportunities-november-2024-university-of-utah-health 2024-11-16T00:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-inc-idya-bcg-matrix-analysis 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-biosciences-inc-idya-bcg-matrix-analysis 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-inc-idya-bcg-matrix-analysis-2024 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-biosciences-inc-idya-bcg-matrix-analysis-2024 2024-11-16T00:00:00+00:00 weekly 0.7